



The miRNA-9 Isoform Story in Cancer: An OncomiR or Tumor Suppressor?

Mahmoud Ibrahim^{1,2,#}, Maryam Abdul-Kader^{2,3,#}, Ava Azizi^{2,4,#}, Evan Schneider^{2,5,#}, Gabriel Salyer^{2,6}, Jill Ivory^{2,7}, Nora Reece-Orr^{2,8}, Heather O'Donnell^{2,9}, Linda Gerace^{2,10}, Zoe Foster^{2,11}, Alan Mariño del Puerto^{2,12}, Yvonne Chen^{2,13}, Brian D. Adams^{2,#,*}

¹Department of Biomedical Engineering, University of Illinois at Chicago, Chicago, IL, USA

²Department of RNA Sciences, The Brain Institute of America, New Haven, CT, USA

³Department of Biological Science, Illinois Institute of Technology, Chicago, IL, USA

⁴Department of Biology, Illinois Institute of Technology, Chicago, IL, USA

⁵Department of Informatics, Northern Kentucky University, Highland Heights, KY, USA

⁶Department of Biology, New College of Florida, Sarasota, FL, USA

⁷Department of Biology, Grove City College, Grove City, PA, USA

⁸Department of Communication, Media and Theatre, Northeastern Illinois University, Chicago, IL, USA

⁹Department of English, Rutgers University, New Brunswick, NJ, USA

¹⁰Department of English, Southern New Hampshire University, Manchester, NH, USA

¹¹Department of Biology, Washington University in St. Louis, St. Louis, MO, USA

¹²College of Natural Sciences, Minerva University, San Francisco, CA, USA

¹³Department of Biology, Brandeis University, Waltham, MA, USA

#These authors contributed equally to the work

*Corresponding author: Brian D. Adams, brian.adams@braininstituteamerica.com

Article history

Received: 30 November 2024

Revised: 11 February 2025

Accepted: 3 April 2024

Published online: 9 April 2025

Keywords

miRNA

Therapy

Cancer

miR-9

Tumor Suppressor

Onco-miR


Neurology

Brain

Abstract

MicroRNAs (miRNAs) are small, non-coding RNA molecules that regulate gene expression post-transcriptionally. They function by binding to newly transcribed mRNAs of protein-coding genes, suppressing gene expression at the post-transcriptional level. Thus, miRNAs play a crucial role in controlling a plethora of cellular processes, making miRNAs a unique class of regulatory RNA with defined developmental roles. Thus, these small yet powerful miRNAs have garnered the attention of many researchers due to the known biological regulatory role during chronic disease onset, including cancer. Over the past decade, novel small RNA therapies have been developed and implemented successfully in the clinic to combat several chronic disorders. With respect to cancer, a number of miRNAs were demonstrated to be correlated with cancer progression and disease onset. These oncomiRs or tumor suppressors control well conserved protein signaling cascades that become dysregulated during the tumorigenic process. In particular miR-9 has garnered much attention over the past decade due to the abundance of this miRNA in certain tissues such as the brain and the epithelium. In this review, we discuss the importance of miRNAs in cancer, the biology of miR-9 in a variety of cancers, explain how the term 'oncomiR' or 'tumor suppressor miR' depends upon the cellular context of gene expression during oncogenesis, and how the abundance of certain miR-9 isoforms in the cell during the initiating tumorigenic event could influence the molecular heterogeneity of the tumor. Additionally, next-generation miRNA therapeutics offer promising strategies for cancer treatment by the precise targeting of disease-related pathways with minimal toxicity and off-target effects. These strategies can also serve as solutions in situations where chemo- and radio-resistance persists.

Graphical Abstract

**Graphical Abstract.** An Overview of miR-9 Biogenesis and Function During Tumorigenesis.

miRNAs are powerful regulators of gene expression in mammalian systems. miRNAs are processed in the cell by Drosha and Dicer that results in an 18-22nt duplex RNA. This duplex gets unwound by AGO proteins where one strand is selected to mediate cellular function by binding to cognate target mRNAs through Watson-Crick base pairing. Many times Dicer cleavage may be incomplete, or the sequence of the miRNA originating from a separate genomic loci may contain some repetitive sequence near the 5' or 3' ends of the eventual miRNA duplex. These miRNA isoforms can influence strand selection of the duplex, ultimately affecting which mRNAs are targeted for degradation. As an example, miR-9 has various known isoforms, with each mature strand controlling different components of neural progenitor regeneration, synaptic transmission, and even drug resistance in cancer.

1. Introduction

MicroRNAs (miRNAs) regulate gene expression patterns during normal developmental processes, as best exemplified during normal *C. elegans* larval development [1-4]. From these early studies researchers elucidated that the dysregulation of even a single miRNA can have drastic effects on the abundance of hundreds of cognate target mRNA species [5-8]. In diseases such as cancer, miRNAs have been classified simply as oncomiRs or tumor suppressors based on the regulatory actions imposed on then known protein-coding tumor suppressor genes and oncogenes, respectively. However, this oversimplification of miRNA function has limited our understanding of how these complex regulatory agents control the signaling pathways that influence the tumorigenic process. Furthermore, despite the efforts of research scientists over the past four decades, neoplasms still remain a top cause of mortality worldwide [9-11]. Therefore understanding new genetic pathways, such as miRNA and other non-coding RNAs [12], may yield novel RNA-based therapeutics with the potential to cure individuals that have cancer. Returning to miRNA function, firstly, over half of the known miRNA genes are located within genomic regions associated with cancer, or within genomic fragile sites prone to chromosomal breakpoints [13-15]. Fragile sites, chromosomal breakpoints, and translocations present within hematological tumors were where some of the the first cancer-associated miRNAs were functionally identified. From there, early cloning and deep sequence studies identified thousands of abundant, mature, 18-22 nucleotide miRNA sequences with unknown function [16-19]. The abnormal expression patterns of these miRNA species across many cancer types indicated that

miRNAs contributed to, or at least correlated with, cancer progression. After decades of research, the methodology to identify these miRNA have developed significantly, from early microarray expression technology, to complex strategies that capture and deep sequence both miRNAs and miRNA sequence variants. This process allowed for the generation of tissue-specific small RNA libraries from limited biospecimen sources, such as tumor biopsies, serum, cerebrospinal fluid, and dermal tissue punch biopsies [20]. These strategies have allowed researchers to further elucidate how non-coding RNAs profoundly impact disease onset, development, progression, and drug sensitivity.

From the early research studies in the field of liquid and blood-related tumors, a small handful of miRNAs were identified to have direct regulatory action during leukemogenesis. Once researchers studying cancers of the epithelium from organ sites, such as the prostate, breast, gastric, lung, and thyroid, appreciated the involvement of miRNAs in cancer, hundreds of conserved miRNA-protein coding gene networks have been identified to directly contribute to the development of tissue-specific carcinomas [21-26]. Again, the first evidence that miRNAs were dysregulated in cancer stemmed from the work of Croce and Calin *et. al.*, who identified miRNA dysregulation was present in chronic lymphocytic leukemia (CLL) [27-31]. Their pioneering research in the early 2000s revealed that deletions on chromosome 13q14.3 led to the loss of miR-15a and miR-16-1. These miRNAs directly bind and target anti-apoptotic genes such as BCL2. Therefore, the loss of miR-15a and miR-16-1 results in enhanced BCL2 expression, thereby promoting tumor cell survival [32-34]. This discovery not only highlighted the tumor

suppressive role of certain miRNAs, but also paved the way for researchers to continue elucidating the involvement of miRNAs within hematological malignancies as well as in epithelial carcinomas.

MiRNA research has yielded promising clinical diagnostics due to the production of biomolecules that can serve as both therapeutic agents as well as disease biomarkers [35-38]. The astounding breakthroughs in RNA chemistry over the past decade have allowed researchers to develop RNA based compounds that have superior clinical benefit when compared to standard gene therapy approaches. For the miRNA field, scientists have found that tumor tissues often display noticeably reduced expression of certain miRNAs, therefore, miRNA mimics are being developed to restore miRNA levels in cancer patients. Additionally, when miRNAs are found to be in over abundance and contribute to tumorigenesis, miRNA sponges are being developed to disrupt the activity of these miRNAs that support tumorigenesis. The quality of these synthetic small RNA molecules depends on our understanding of the mechanisms that cause cessation or overabundance of miRNA expression, which includes genetic alteration, epigenetic silencing, and miRNA biogenesis pathway defects.

Yet how do miRNAs truly function? As will be explained in more detail below, miRNAs are small endogenous non-coding RNAs, usually 18-22 nucleotides long, that negatively regulate protein-coding gene expression post-transcriptionally (see Figure 1). Importantly, miRNAs are necessary for the regulation of gene expression and fine tuning of almost all biological processes [39-44]. The genes that encode a mature miRNA sequence begin with a transcribed region of the genome that yields a primary miRNA (pri-miRNAs). This polycistronic sequence is then sequentially processed by a series of RNaseIII catalytic enzymes, such as DROSHA, into precursor miRNAs (pre-miRNAs) of around 70-80 nucleotides. Sequentially, the RNaseIII enzyme DICER, converts these pre-miRNAs to a mature miRNA sequence of around 19-23 nucleotides [40,45-47]. The miRNA duplex undergoes an event called strand selection, whereby one strand of the duplex is bound to an RNA-induced silencing complex, which is then guided to the 3' of the untranslated region (UTR) of a cognate target mRNA (see Figure 1). This interaction results in the post transcriptional repression of a cognate mRNA target, or the direct cleavage and degradation of the mRNA target.




Figure 1. The Various Mechanisms that Modulate the Generation of the Final miRNA Strand.

This figure depicts the numerous ways in which miRNAs can be generated. Panel 1, shows the canonical miRNA biogenesis pathway. Here pri-miRNAs transcribed from the genome are processed by DROSHA into an 85nt stem loop, which is recognized by DICER generating a 22 nt duplex [48-53]. Strand selection occurs after binding to AGO, allowing for target mRNA degradation. In Panel 2, miRNAs are generated from introns of protein coding genes. During splicing and lariat formation, a pre-miRNA is formed that bypasses Drosha [54-56]. When this hairpin is loaded into Dicer, the released hairpin becomes the mature miRNA bypassing strand selection and gets loaded into AGO. In Panel 3, during miRNA biogenesis, both DROSHA and DICER can cleave the pre-miRNA in an offset manner by up to 2-3 nucleotides [57-62]. These trimming errors create miRNA isoforms that affect miRNA-mRNA stability, but could also affect strand selection, as trimming occurs at the 5' and 3' ends of the miRNA.

One should appreciate that miRNA interactions are dynamic and are dependent on a variety of factors such as subcellular localization, strength of the interaction between the miRNA and the cognate mRNA target, as well as the abundance of the miRNA and target mRNAs [63-67]. Additionally, miRNA expression becomes dysregulated in human cancer through faulty miRNA transcription, aberrant DNA methylation, miRNA gene amplification or deletion, as well as defects in miRNA

biogenesis [68-71]. The fact that miRNA activity depends upon both a miRNA sequence and protein coding gene abundance, explains why it is difficult for many researchers to pin down the exact causality for a miRNA-related cancerous origin. This hypothesis is of course being compared to a more simplistic understanding of tumorigenesis such as a mutation in one protein coding gene such as *TP53*, or *MYC* that results in a pro-tumorigenic event. In support of this notion,

dysregulation of miRNA abundance and activity has been shown repeatedly to be a key player during cancer oncogenesis by controlling cellular differentiation, sustaining proliferation, evading growth suppressors, and resisting apoptosis [72-79]. An example of this miRNA dysregulation is exemplified during glioma malignancy, where dysregulation and mutation of miRNAs may be related to glioma formation, and furthermore the use of miRNAs are being developed into biomarkers for glioma progression [80-89]. Because of research studies such as this, miRNAs are seen as a potential therapeutic for glioblastoma due to their regulation of many known cancer-associated mRNAs. As mentioned earlier, once identified, the altered miRNAs within a tumor can be therapeutically manipulated resulting in a correction of miRNA activity and subsequently, a restoration of the normal cellular signalling processes [90-93]. The hope for a targeted miRNA therapy has been met with some challenges due to organ specific delivery, yet the discovery of miRNA containing exosomes have helped researchers elucidate new strategies for miRNA delivery in the clinic.

2. Mirna Biogenesis

The biogenesis of miRNAs involves a series of intricate enzymatic RNA processing steps. In most organisms, this is a conserved regulatory process, yet there are some nuanced steps that occur in mammalian systems. As explained earlier, miRNAs are encoded within the genome and are found at multiple genomic loci. These genetic loci are transcribed by RNA polymerase II, as most other protein coding genes, and the resulting transcript is 5' methyl-guanine capped and 3' polyadenylated [47,94]. However, these pri-miRNA transcripts form polycistronic hairpin structures that attract type 2 RNase III enzymes that recognize these double stranded RNA sequence hairpins (see Figure 1). As an example, the DROSHA-DGCR8 complex recognizes the polycistronic hairpins within the pri-miRNA and releases these newly formed pre-miRNAs from the nucleus to the cytoplasm [40,45-47]. Cytoplasmic import of nuclear pre-miRNAs are facilitated by a nuclear pore protein termed exportin-5, which also functions as a protector from nucleolytic attack by other RNase enzymes tasked with preventing the accumulation of nuclear RNAs.

While this is a slightly ambiguous process, these pre-miRNAs are recruited mostly to the cytoplasmic regions near the rough endoplasmic reticulum where protein producing polysomes are found. At this stage the pre-miRNA is recognized and further cleaved by another RNase III endonuclease called DICER [48,49]. This occurs because the DICER endonuclease is able to recognize the 2-nucleotide 3' overhang of the stem loop, as well as the unpaired terminal stem loop causing cleavage and release of a 19-23-nucleotide mature double strand miRNA duplex (see Figure 1). Specifically researchers identified that the PAZ (PIWI-AGO-ZWILLE) domain of DICER functions as a "molecular ruler", aiding in miRNA-duplex generation with inset 5'-phosphates and 2-nucleotide 3' overhangs [50-53,95-97].

This also indicates that DICER-mediated miRNA trimming is the key to ensuring precise mature miRNA length and proper functionality.

Occasionally, miRNA precursors are transcribed with additional nucleotides on each end, resulting in extended transcripts. Usually DROSHA can trim the precursor miRNA molecule to remove these additional nucleotides since the embedded miRNA duplex in the pre-miRNA is guiding the RNaseIII-mediated slicing process [50-52]. However, there are errors during this process and researchers have reported miRNA sequences outside the normal defined lengths, with unknown regulatory effects. Now, if DROSHA and DICER fail to properly trim these miRNA precursors during the biogenesis process, and before duplex strand-selection, a larger miRNA with varied sequences would be produced. This longer than normal miRNA could have altered interactions with target cognate mRNAs, or even fail to be incorporated into the RNA-induced silencing complex altogether. In fact, it has been observed that oversized miRNA tends to be unstable, have altered subcellular localization, and differential interactions with regulatory proteins, which could greatly disrupt normal cellular function [98-100]. The link between improperly trimmed miRNAs and disease such as cancer, have yet to be fully elucidated, and is an exciting area of miRNA research.

Furthermore, dysregulation of key enzymes involved in miRNA processing, such as DROSHA and DICER, have been studied, and are known to disrupt the precise processing of miRNA precursors [101-113]. Additionally, genetic mutations within miRNA sequences or regulatory regions could alter the secondary structures of these enzymes, thereby inhibiting the proper formation of duplex-miRNA strands. Environmental factors, such as cellular stress or exposure to toxins may also affect this miRNA biogenesis process [114,115]. Any disruption in the mature-miRNA duplex could impair these miRNAs from properly loading into the RNA-induced silencing complex (RISC) and subsequently properly targeting the appropriate cognate mRNAs. This disruption in miRNA biogenesis could therefore result in cancer development.

3. Variations in Mirna Biogenesis

Returning to miRNA biogenesis, one very important step is strand selection of the miRNA duplex. As mentioned earlier, a typical miRNA-duplex contains an inset 5'-phosphate and a 2-nucleotide 3' overhang (see Figure 2). This overhang is important as the strand with more instability on one of the duplexed ends (i.e., less base pairing) gets preferentially loaded into the RISC complex, which contains an Argonaute protein (AGO). Because this strand now serves as the guide strand, these predominant strands would interact with target mRNAs through Watson-Crick base-pairing. However, if the opposite strand of the duplex is selected instead, then a completely new set of cognate mRNA targets would now be regulated by this miRNA. Because of this dynamic, the old nomenclature of calling a miRNA duplex a guide strand (i.e., dominant) or star strand (i.e., degraded strand) is outdated. Researchers now use the terms -5p or -3p

based on the location of the mature miRNA on the pre-miRNA stem loop (see Figure 2). Another reason for this new nomenclature, is that during normal cellular processes, (i.e. non cancerous tissue), deep sequencing

studies have found that -5p mature miRNA sequences are expressed at times at almost similar levels to the -3p mature miRNA from the same miRNA stem loop precursor.




Figure 2. Genomic Loci of the miR-9 Host Genes and Isoform Characteristics.

This figure depicts the genomic loci from which miR-9 derives (green text). The miR-9 host gene is located on chromosomes 1, 5, and 15 respectively, with each miR-9 gene being processed into a pre-miRNA hairpin. The 85 nucleotide hairpin reads from deep sequencing are similar across all three isoforms. While all hairpins share similar configuration, the miR-9-3 isoform yields a miRNA duplex with equivalent 3' overhangs of 2 nucleotides each (shown in blue text and inset duplex diagram). This equivalency indicates balanced loading of miR-9 guide (-5p) and star (-3p) strands into the RISC complex, and therefore balanced loading into AGO2 complexes for mRNA targeting. A number of complex factor effects isoform abundance including DNA methylation, gene amplification, chromosomal abnormalities, and RNA trimming / editing.

These are fascinating discoveries and there may be some evolutionary explanations for how miRNA biogenesis and strand selection commences. First, the conservation of both miRNA precursors and certain mature miRNA strands across different species, sheds light on the evolutionary origins and functional significance of most miRNAs [116-118]. These mechanisms remain almost unchanged throughout thousands of years of evolution, and some miRNA sequences can be found in almost all species across nature in both plants and animals [118-120]. Additionally, the miRNA biogenesis machinery is also highly conserved across species, indicating miRNA regulatory pathways co-evolved with protein coding genes since the earliest known cellular organism. From a selfish genetic perspective, it is clear that mutations in the 3'UTR of genetic elements occur to avoid regulation by miRNAs, and in turn miRNA isoforms may be selected for, so as to keep these genetic elements in check. As a result of this complex interplay, emergence of families of miRNAs, miRNA duplications, and miRNA isoforms that share a similar sequence and function developed within the genome [121,122].

Finally, recent studies have found alternative miRNA biogenesis pathways that can yield new forms of miRNAs. Partly, this has to do with mutations of canonical miRNA processing genes such as DROSHA and DICER, which have been shown to play a role in developmental abnormalities and cancer [123-129]. Additionally, researchers have also identified specific RNA-binding proteins such as HnRNPA1, SMAD1 and SMAD5 to be important regulators of the miRNA biogenesis pathway, where in some cases the processing

of A or G sequence rich pre-miRNAs becomes disrupted [130-136]. However, the most recent discovery is that alternative miRNA species called miRtrons can be formed during the mRNA splicing process due to the secondary structure of some intronic genetic sequences [42]. Importantly these short hairpin introns completely bypass DROSHA processing and can be loaded directly into DICER for further miRNA maturation. This phenomenon was first discovered in Drosophila and then found to occur throughout the animal kingdom, indicating this conserved pathway has evolved for the same reasons as canonical miRNA sequences, and indicates their crucial role in gene regulation [137-139]. To reiterate the importance of miRtrons, these hairpin structures are formed from short intronic sequences of protein-coding genes that are spliced during transcription forming lariat structures [54]. This means that miRtrons and the host protein coding gene may also exist in a co-evolutionary biochemical relationship. Also, because these hairpin structures bypass the DROSHA-DGCR8 complex, the short intronic lariats formed during the splicing must be debranched by the enzyme DBR1 in the nucleus, before being transported to the cytoplasm by Exportin-5. This indicates that there are still more biogenesis related genes that control miRNA production, and as such, represent another series of genetic elements that can become dysregulated during tumorigenesis. Finally, miRtrons are somewhat different than canonical miRNAs in that the mature miRNA sequence in miRtrons reside on the terminal loop of the pre-miRNA, extending from the 5' arm to the 3' stem (corresponding to guide and passenger strands) [55,56]. Therefore, there is almost no occurrence of strand selection during

DICER processing of a miRtron. Taken together, by understanding these nuanced biochemical processing steps, RNA researchers can uncover new species of RNA, initiate the development of novel biomarkers of disease, as well as to build innovative targets for therapeutic intervention.

4. Mirna Isoforms and Gene Duplication

In many cases, miRNA transcripts naturally contain sequence variations, called microRNA isoforms (isomiRs). These variations can be caused by inaccurate DROSHA or DICER cleavage or insertion mutations [140-142], but are usually not the result of trimming as depicted above. IsomiR abundance varies due to many factors, including cell type, tissue of origin, and other epigenetic factors. Although isomiRs are common, their broader biological significance is not fully understood; there are numerous databases that have compiled this miRNA sequence information, and data on isomiRs are limited due to the current methodological approaches utilized to accurately capture and quantify their abundance [140]. From the few studies that have investigated isomiR function, it seems isomiRs have a wide range of biological effects including the dysregulation of miRNA targeting, influencing strand selection, and altering the stability of miRNA bound RISC complexes.

IsomiRs can be classified in four ways in reference to the template sequence: a nucleotide variation, the length of the 5' end of the miRNA sequence, a shorter or longer miRNA 3' end, and/or a post-transcriptional RNA modification [57-61]. IsomiRs that contain the multiple characteristics noted above are identified as multi-variant isomiRs. From what little is known regarding isomiR formation, it is generally assumed that nucleotidyl transferases, which make edits to the RNA sequence during miRNA maturation, partly account for this variant formation [62]. Moreover, these edits tend to result in sequence variations at the 3' end of the miRNA, which affect miRNA targeting efficacy rather than the target cognate mRNA repertoire. Researchers have found that there is a positive selection pressure for isomiR retention as these variants increase miRNA diversity and maintain a dynamic non-coding RNA regulatory network [143-149]. Clearly, isomiR expression and function is strongly related to their respective homologous miRNA, and may even function to prevent repressive genetic elements from silencing this respective miRNA gene loci [150]. The expression of isomiRs also varies in certain cells and tissues, resulting in many different physiological outcomes, such as variant accumulation in certain types of cancer.

A great example of a canonical miRNA that has a number of iso-variants is miR-9. miR-9 plays a pivotal role in neural development by targeting key transcription factors such as, HES/HER and ERK1/2 [151]. In zebrafish, miR-9 expression and activity modulates HER6 transcriptional dynamics, maintaining a low or noisy oscillatory range of gene expression. When neural progenitors remain in an undifferentiated state, miR-9 levels tend to be low. Yet, during differentiation miR-9

levels rapidly increase causing a dramatic decrease in HER6 activity allowing for late-stage neuronal differentiation [152,153]. This process depends on the precise levels of miR-9, as deviations in expression can disrupt HES1/HER6 oscillations and the timing of neuronal differentiation in Zebrafish. Notably, vertebrates possess multiple miR-9 loci, each maintaining a respective temporal and spatial gene expression pattern (see Figure 2) [154-160]. Given what is known regarding the quantitative mechanisms that maintain miR-9 activity during Zebrafish neuronal development, one could argue this regulatory pathway is conserved across species including mammals. Specifically, researchers are now investigating how early and late pri-miR-9 transcript isoforms accumulate within the cell, resulting in the enhanced mature miR-9 levels essential for HER6 downregulation and late-stage neuronal differentiation [161-167]. These studies underscore how intricately nuanced a non-coding RNA regulatory framework can be. Understanding both the qualitative and quantitative contributions of pri-miR-9 isoforms during neural development is crucial in elucidating which molecular pathways found to be disrupted in cancer are miR-9 dependent.

Some investigators have assessed the 3D structural characteristics of pri-miRNAs to determine how certain RNA motifs are recognized by DROSHA, and what moieties may influence the precise cleavage of the pre-miRNA stem loop [168-170]. Researchers argue that the flexibility within the lower-stem portion of the hairpin within the pri-miRNA creates a base pairing distortion influencing the accuracy of nucleotide cleavage. This structural ambiguity is observed with miR-9 itself, given certain miR-9 paralogs have non-equivalent 3' overhangs post DICER cleavage (see Figure 2). Because of this ambiguity, strand separation of the miRNA duplex is a much more stochastic process. This indicates that both DROSHA and DICER require precision for proper catalytic function, and that any sequence variation can destabilize the fidelity of these RNaseIII enzymes, adding complexity to the regulation of miRNA biogenesis [168-170].

5. The Cell Context Expression of Mirnas

Researchers now understand that the processing of miRNAs, including isomiR variants, is a tissue-specific process, which has profound and significant biological implications. The seemingly ubiquitous expression pattern of miR-9 and miR-9 variants in the nervous system seemingly argues against this notion [171]. However, miR-9 variants are somewhat differentially abundant in other tissue types (see Figure 3). Importantly, in pathological states, the presence of certain miRNA isoforms predominant for a number of reasons. miR-9-5p for instance is clearly present in low-grade glioma datasets, underscoring the potential for this miRNA to be a *bona-fide* cancer-specific biomarker. However, in AML, miR-9-3p is present at much higher levels and is directly attributable to leukemogenesis. Again the reason for the biased miRNA isoform expression in each of these tissues is not well understood, however some

studies indicate the occurrence of "miRNA-editing-hotspots," in cancerous tissues, with RNA editing levels at rates above 5% in some tumor types [172-178]. Furthermore, from an analysis of 8,595 TCGA samples

across 20 tumor types, miRNA-editing hotspots correlated with the expression of known oncogenes, emphasizing the relevance of miRNA modifications during the process of tumorigenesis.




Figure 3. Normal Tissue Specific miR-9 Expression Patterns and Top Ten mRNA Targets. This figure depicts a more balanced way of assessing miRNA isoform strand abundance via tissue specific sequencing, as opposed to the original whole organism cloning analysis. Here we find miR-9-5p and miR-9-3p are both abundantly expressed in heart, brain, and lung tissue. miR-9-3p is expressed in general slightly less than miR-9-5p, yet the presence of both isoforms in these tissues supports the notion of equivalent loading into AGO complexes. The top ten predicted targets of miR-9-5p and miR-9-3p are also shown on the right panel, with a known miR-9-5p target M6PR shown to be biochemically linked with AGO2 via CLIP-seq data. These data support that both miR-9 strands are contributing to stochastic gene regulation that can promote or suppress tumorigenesis in epithelia tissue.

Together, these findings highlight the intricate regulatory processes that control miRNA abundance, which includes RNA-editing, trimming, and strand selection, all of which contribute to the miRNA functional diversity within the cell. These unique isoforms and imperfect duplexing of miR-9 pre-miRNAs further complicate the process of strand selection between miR-9-5p and miR-9-3p, and potentially explains the differential abundance of these isoforms in specific tissues. These insights into the processing and editing of miR-9 and related miRNA isoforms not only enhances our understanding of miRNA biogenesis but also reveals new genetic regulatory loops that are actively occurring during normal development, as well as disease pathogenesis. Elucidating these regulatory loops will inform clinical scientists as to how to develop effective therapeutics involving non-coding RNA agents.

6. The MiR-9 Family

As mentioned above, miR-9 is a unique miRNA molecule expressed in a specific group of inactive radial glial cells. miR-9 is one of the most expressed miRNAs within the developing brains of adult humans (see Figure 3), and plays a crucial role in maintaining cell quiescence by regulating gene expression signaling pathways such as NOTCH and FOXG1 [179,180]. As is typical of most miRNAs, miR-9 functions as a developmental lock operating as a protective feature allowing for the proper proliferation and self renewal of neural progenitor cells.

The regulators of miR-9 would then serve as the key to initiate a repertoire of cellular functions during neuronal specialization. The diversity of miRNA function is quite striking as miR-9 controls neuronal migration, differentiation, proliferation and apoptosis, while the loss of miR-9 plays a central role in neurodegenerative disease [181].

miR-9 is also a highly conserved miRNA and studies in model organisms such as *Xenopus laevis*, *Danio rerio* (zebrafish), and *Mus musculus* (mice) indicated that miR-9 is essential for cell fate transitions during neurogenesis by post-transcriptionally regulating the transcription factors FOXG1 and TLX1 [182-185]. Interestingly, during zebrafish neurogenesis, the amount of mature miR-9 increases in a sharp, stepwise manner, driven by the sequential expression of seven distinct pri-miR-9 transcripts. Furthermore, the expression of late-onset pri-miR-9-4 and -9-5 transcripts in individual cells, underscoring the importance of a redundant positive feed-forward expression program vital for zebrafish neurogenesis [167]. Notably, CRISPR/Cas9-mediated disruption of pri-miR-9-1 locus impairs the developmental increase of mature miR-9, resulting in the inability of neurons to downregulate HER6 and subsequently causes a reduction in late stage neuronal differentiation. This knockout model emphasizes the precise temporal and spatial regulation of miR-9 as a fundamental regulatory mechanism during neurogenesis [186]. Beyond the role of miR-9 in neural progenitors,

miR-9 controls dendritic cell growth and synaptic transmission *in vivo*. Downregulation of the transcriptional repressor REST, mediated by miR-9, is necessary for proper development and growth of neuronal dendrites [187]. miR-9 is also linked with spinal cord development in vertebrates by controlling FOXP1 and ONECUT1. This suggests that miR-9 is critically important in motor neuron development [188,189]. However, given miR-9 is expressed in the forebrain, midbrain, and hindbrain of developing animals, it is clear that the spatiotemporal expression and activity of miR-9 plays an important role in many neurological disorders, as well as in supporting normal neurocognitive phenotypes. Overall, miR-9 regulates multiple anatomical-specific genes within the brain in a precise spatiotemporal manner during vertebrate neural development.

7. The Context Dependent Regulatory Action of MiR-9 in Cancer

The context-dependent regulatory action of miR-9 in cancer highlights a dual role for miR-9, as both a tumor suppressor and an oncogene. The actions of miR-9 in supporting or repressing tumorigenesis really depends upon the cancer type as well as the molecular environment, meaning the abundance of the cognate target cellular mRNA profile [190]. miR-9 exerts its effects through diverse mechanisms, targeting key pathways involved in cellular proliferation, survival, migration, and invasion (see Table 1). For instance, in medulloblastoma miR-9 functions predominantly as a tumor suppressor by downregulating the oncogenic transcription factor TLX1, while simultaneously modulating the NOTCH/STAT signaling pathway [191-194]. In glioma, however, miR-9 often operates as an oncogene, promoting angiogenesis and tumor growth through targets such as COL18A1 and PTCH1 [195]. Similarly, in breast cancer, miR-9 has seemingly conspicuous roles depending upon the cell types that express the miRNA. For instance, miR-9 can suppress growth in 17- β estradiol receptor-positive tumors but may drive a more aggressive triple-negative breast cancer subtype by promoting MAPK signalling. This seemingly dual functionality extends to other cancers, including gastric, prostate, and blood tumors, where miR-9 regulates either known oncogenic or tumor-suppressive targets such as TNFAIP8L3, StarD13, and NF- κ B signaling [196-198]. The intricate regulation of miR-9 by genetic, epigenetic, and transcriptional co-

factors underscores miR-9 as a potential biomarker and a therapeutic target across many cancers. Further research is required to unravel the complex, and cellular context-specific roles of miR-9 within each cancer subtype.

7.1 Medulloblastoma

In the context of medulloblastoma, miR-9 has garnered significant attention as a potential tumor suppressor (see Table 1). Experimental evidence from *in vitro* and *in vivo* studies has demonstrated that miR-9 negatively regulates critical oncogenic pathways and genes associated with medulloblastoma pathogenesis [199,200]. For instance, miR-9 has been shown to target and downregulate TLX1, a transcription factor implicated in medulloblastoma pathophysiology, thereby attenuating certain anti-tumorigenic effects. Additionally, miR-9 has been reported to modulate other key mediators of cellular proliferation and survival, such as NOTCH1 and STAT signaling, potentially impacting tumor growth and therapy resistance [201,202]. The dysregulation of miR-9 in medulloblastoma may be due to various mechanisms, including genetic alterations, epigenetic modifications, and dysregulation of upstream co-regulatory transcription factors.

In support of miR-9 operating as a tumor suppressor, aberrant DNA methylation and histone modifications near the genomic loci of miR-9 have been observed in medulloblastoma samples, leading to the suppression of miR-9 activity. Moreover, transcriptional regulation mediated by oncogenic transcription factors can also influence miR-9 expression levels, thus contributing to tumor pathogenesis [203,233]. Beyond the role of miR-9 as a tumor suppressor, miR-9 has shown promise as a potential diagnostic and prognostic biomarker for medulloblastoma. Studies have investigated the differential expression of miR-9 in tumor tissues as compared to normal brain tissue, as well as the correlation with clinicopathological features and patient outcomes [203,233]. These studies have shown that miR-9 inversely associates with tumor size, clinical stage, and distance metastasis. Therefore, the further characterization of miR-9 expression patterns in medulloblastoma could aid in refining molecular subtyping and stratification criterion for the disease. Moreover, these findings have implications for developing novel treatment approaches for those medulloblastoma patients with poorer prognosis, such as group 3 and 4 tumor types.

Table 1. Notations of the Various miR-9 Isoforms Involved in Tumorigenesis.

Cancer Type	Tumor Suppressor/Oncogene	Overview	miR-9 Isoform	References
Medulloblastoma	Tumor Suppressor	Downregulates TLX1 Modulates NOTCH1	hsa-miR-9-5p	[199-202]
		Modulates STAT signaling Modulates DNA methylation	hsa-miR-9-5p	
		Downregulated in MB	hsa-miR-9-5p	
Glioma	Oncogene	Promotes angiogenesis Downregulates COL18A1	hsa-miR-9-5p	[195,203-206]
		Downregulates PTCH1 Modulates HIF-1 α /VEGF Upregulated by MYC	hsa-miR-9-5p	
		Upregulated in Glio	hsa-miR-9-5p	
Breast Cancer	Both	Downregulates ERA+ Modulates MAPK	hsa-miR-9-5p	[207-212]
		Promotes tamoxifen-resistance Promotes TNBC phenotype	hsa-miR-9-5p	
		miR-9* suppresses TNBC proliferation and migration	hsa-miR-9-3p	
		miR-9* targets ITGB1 miR-9* targets MEK	hsa-miR-9-3p	
Cervical Cancer	Both	Upregulated in CC/SCC	hsa-miR-9-5p	[213-217]
		Modulates HPV16/18-related	hsa-miR-9-5p	
		Downregulates TWIST1 Downregulates FOXO3	hsa-miR-9-3p	
		Tumor suppressor in AC	hsa-miR-9 ?	
Prostate Cancer	Both	Downregulates StarD13 Downregulates NUMB	hsa-miR-9-5p	[218-221]
		Promotes stemness Promotes proliferation	hsa-miR-9-5p	
		Tumor suppressor functions	hsa-miR-9-3p	
		Downregulates MEKK3 Restores E-cadherin and MET.	hsa-miR-9-3p	
Gastric Cancer	Both	Inhibits migration and invasion	hsa-miR-9-5p	[222-227]
		Targets TNFAIP8L3 & RAB34	hsa-miR-9-5p	
		Upregulates MYH9 due to HULC sponges	hsa-miR-9-3p	
		Targets CDX2 and CDH1 Promotes tumor progression	hsa-miR-9-3p	
Chronic Lymphocytic Leukemia (CLL)	Tumor Suppressor	Downregulated by hypermethylation	hsa-miR-9-5p	[228-230]
		5-AzadC restores miR-9 expression	hsa-miR-9-5p	
		Targets NF- κ B1 Pro-tumor suppressor effects	hsa-miR-9-5p	
Acute Myeloid Leukemia (AML)	Both	Suppresses CXCR4 Promotes G1 arrest and apoptosis	hsa-miR-9-5p	[231,232]
		In MLL/AML miR-9, promotes tumor progression	hsa-miR-9-3p	
		Targets RHOH and RYBP	hsa-miR-9-3p	

* In some cancers it is not clear if miR-9-5p or miR-9-3p drive tumorigenesis as miRNA overexpression stem loop methods as well as gene knockout methods modulate the levels of both miRNA isoforms.

7.2 Glioma

Glioma is characterized by cancerous glial cell growth in the brain or spinal cord, and develops due to unabated angiogenesis and tumorigenesis. The underlying factors that trigger or inhibit these molecular processes is mostly unknown. miR-9 regulates biological processes and cellular pathways that ultimately supports glioma tumorigenesis (see Table 1). Some researchers have indicated glioma as a miR-9 type tumor given the elevated levels of miR-9 that are found in most all glioblastoma tumor tissue. Furthermore, miR-9 promotes the enhanced proliferation, migration, and invasion of glioma cells by targeting COL18A1, THBS2, PTCH1 and PHD3 [68,184,195]. Interestingly, miR-9 can be transported within exosomes and absorbed by vascular endothelial cells, increasing tumor angiogenesis, one of the hallmarks of aggressive drug-resistant glioblastoma.

The mechanisms supporting persistent miR-9 expression in glioblastoma may be related to the structure of the miR-9 genes. Studies have shown that MYC and OCT4 can bind to the miR-9 promoter and transcriptionally activate miR-9 in an uncontrolled manner [204,205]. This mechanism would support the uncontrolled proliferation and expansion of neural progenitor cells. According to the two hit model of tumorigenesis, if a second mutation occurred within this expanded stem cell pool, the formation of an aggressive undifferentiated glioblastoma could easily develop. Therefore, it should be appreciated that miRNAs may be indirect drivers of tumorigenesis by facilitating an environment that favors tumorigenic development and progression.

What is less understood is how each miR-9 isoform contributes to tumorigenesis. In the case of both medulloblastoma and glioblastoma it is clear miR-9-5p is driving a tumor suppressive and oncogenic phenotype, respectively. This indicates that the cognate target mRNAs expressed in each cell type is an important determinate of miR-9 function in these cancers. Of course many researchers have not fully investigated the functional consequence of miR-9-3p in these tumors.

Despite these limitations, the use of miR-9 as a therapeutic for glioma is becoming a reality due to the fundamental role of miR-9 in glioma pathogenesis. Researchers know that miR-9 directly targets the 3'-UTRs of COL18A1, THBS2, PTCH1, and PHD3, degrading these mRNAs and disrupting HIF-1 α /VEGF signaling [195]. This regulatory effect is crucial in developing miR-9 as a therapeutic given angiogenesis is a major contributing factor supporting malignant glioblastoma [68]. What has limited miR-9 as a therapy for various forms of brain cancer involves the effective delivery of the therapeutic oligonucleotide to the brain tissue, and importantly ensuring that the RNA entity effectively inhibits only the pro-tumorigenic functions of the miRNA. Therefore newer oligonucleotides have been developed to only express one miRNA-strand, an anti-miR that effectively blocks miRNA activity, or an oligonucleotide that only disrupts one miRNA-mRNA pairing. These findings highlight miR-9 as a potential target for glioma diagnosis and therapy.

7.3 Breast Cancer

miR-9 has a pivotal role in breast cancer development, as the targets of miR-9 are clearly cell context dependent. Similar to the neuronal system, and perhaps more prevalent, miR-9 has been shown to target ER α [234-238]. Similar to miR-206[23], the regulation of ER α by miR-9 indicates that miR-9 not only functions as a tumor suppressor in 17- β -estradiol addicted hormone positive breast cancer, but may also serve as a promoter of an oncogenic event by promoting the formation of a triple negative breast cancer cell [180]. This process seems paradoxical, yet one must understand that very few proliferative cells of the mammary gland are in fact ER α +. A majority of the dormant mammary stem cell pool are ER α -. Similar to glioblastoma, if miR-9 expression supports stem cell expansion in these cell types, then a second oncogenic mutation would result in the formation of an ER α -, hormone independent breast cancer. In support of this hypothesis, the forced expression of miR-9 in ER+ MCF-7 cells, results in an initial decrease in cell proliferation, however prolonged exposure to miR-9 results in the emergence of MCF-7 tamoxifen resistant cells [207-209,234]. Furthermore, these new cells also take on the characteristics of a more stem/precursor cell phenotype. Therefore, we suspect the best utilization of a miR-9 therapy would be an anti-miR-9 in patients with tamoxifen resistance tumors.

Despite this assumption above, a major question remains as to what form of miR-9 therapy should be implemented (see Table 1). Returning to the concern of miR-9 isoforms, in the experiments above, a lentivirus containing a miR-9 precursor stem loop was utilized. This means that both miR-9-5p and miR-9-3p strands are being expressed at abundant levels in these MCF-7 cells. Many researchers do not assess the targets of miR-9-3p in these studies, only the associated loss of ER α due to miR-9-5p targeting [210,239]. Therefore, miR-9-3p could serve as a substrate for a miRNA-based therapy in tamoxifen resistant breast cancer by sponging and blocking miR-9-5p function [239].

Interestingly, some have reported that the entire genetic miR-9 locus is hypermethylated in TNBC tumors given miR-9 can target the MAPK pathway. It is known that TNBC cells rely on MAPK for growth and proliferation [211,212]. Yet what does this mean for the expression of miR-9-5p and miR-9-3p isoforms? Further research shows that miR-9 is expressed from three distinct genetic loci, and therefore this reported hypermethylation may not be a complete process (see Figure 2). To circumvent the concern of a miR-9 mimic therapy supporting tamoxifen resistance in ER α tumors, the use of a miR-9-3p therapeutic could have superior potential in the clinic. In fact, miR-9-3p appears to not have pro-growth roles in TNBC, and miR-9-3p has been shown to suppress growth and proliferation of TNBC cells in combination with a MEK inhibitor. Also, by regulating the ITGB1, miR-9-3p also appears to influence and abate TNBC cellular migration, a key feature of metastatic ER α -breast cancer.

The data suggest that the biological processes of miRNAs are seemingly far more complex than originally

anticipated. However, the methods utilized to study miRNA-mRNA regulation *in vitro* [236], does not always translate to the effects mediated by a chemically modified single strand oligonucleotide. In fact, the notion of using a stable miRNA isoform to sponge culprit miRNAs during tumorigenesis may be a more practical therapeutic approach rather than standard miRNA therapeutic strategy that brings about the concern of modulating numerous mRNA, causing off-target effects.

7.4 Cervical Cancer

Cervical cancer is the fourth most common cancer among women worldwide, with over 570,000 new cases and more than 311,000 deaths reported annually [213]. A number of miRNAs have been associated with cervical cancer progression and drug response, and shown to play critical roles in regulating gene expression and influencing disease outcomes. Specifically, miR-9, along with miR-21 and miR-155, are significantly overexpressed in cervical cancer tissues compared to normal tissues (see Table 1) [213,214]. During cervical cancer development, deregulation of miRNAs, including miR-9-5p, contributed to aberrant gene expression. Interestingly, miR-9-5p associates with a high-risk human papillomavirus (hr-HPV)-type-dependent expression pattern, and functions as an oncogene in squamous cervical carcinomas, while potentially promoting a tumor suppressor phenotype in cervical adenocarcinomas. This dual functional role of miR-9-5p underscores the complexity of miR-9-5p regulation and highlights the potential of certain miR-9 variants as diagnostic and therapeutic targets in cervical cancer.

Again, both miR-9-5p and miR-9-3p isoforms are expressed in normal cervical tissue (see Figure 3), however, most researchers only focus on the presumed predominant miR-9-5p isoform. This could be due to the fact that persistent infection with hrHPV, particularly HPV16 and HPV18, results in extremely elevated levels of miR-9-5p [213-217,240]. While HPV is one of the primary causes of cervical cancer, many other cancer subtypes can emerge absent of HPV infection. Given we know miR-9 functions in different capacities given the pathological subtypes of cervical cancer, (i.e., squamous cell carcinoma versus adenocarcinoma), it would also be important to know if certain miR-9 variants are correlated or anti-correlated with HPV. Given squamous cell carcinomas account for approximately 80% of cervical cancer cases [213,241], understanding the role of miR-9 in this cellular context is quite important (see Table 1). This is mostly due to the hyperfocus on elucidating the molecular underpinnings of epithelial cervical adenocarcinomas which is driven by HPV infection. In support of this, in squamous cancers of the head and neck it seems miR-9 functions as a tumor suppressor by stalling cell cycle. Therefore one cannot simply assume that miR-9 operates as a tumor suppressor or oncogene solely based on the histological categorization of the tumor. Moreover, an in depth study of all known miR-9 variants should be performed in future tumor expression studies so as to fully understand the dominant isoform variants that may be driving the

tumorigenic process through specific and undiscovered regulation of cognate mRNA gene targets.

7.5 Prostate Cancer

Prostate cancer is one of the most common types of cancer in men, and a leading cause of cancer mortality among men [242,243]. miR-9 expression has been shown to impact prostate cancer biology and progression (see Table 1). More specifically in DU145 and PC-3 cell lines, miR-9 promotes cell proliferation, invasion, and epithelial to mesenchymal transition (EMT), promoting cancer progression [218-220]. The pro-oncogenic effects of miR-9 are due to the direct targeting of StarD13, a known tumor suppressor gene. Furthermore, in prostate cancer cells, miR-9 and StarD13 expression levels are anti-correlated [198], further supporting the notion that StarD13 is one of the main targets of miR-9.

A common theme in epithelial tumors is the loss of cellular polarity and the acquisition of a migratory and mesenchymal phenotype. Interestingly, the restoration of StarD13 by miR-9 inhibition results in upregulation of E-cadherin, a critical tumor suppressor protein responsible for maintaining cell-cell adhesion and cellularity polarity. This approach also results in increased N-cadherin and a decrease of vimentin expression, indicating a complete reversal of the EMT process. Therefore inhibition of miR-9 may very well be a valid therapeutic strategy to stall prostate cancer progression.

Another mechanism of action by miR-9 in prostate cancer involves CD44. Specifically, some studies have shown that miR-9 is significantly upregulated in CD44+ prostate cancer stem cells (PCSC) by suppressing the tumor suppressor NUMB [198]. Although it is unclear which miR-9 isoforms play a role in this process, it is clear that forced expression of miR-9 (via lentivirus continuing a miR-9 stem loop), promoted stemness in PCSCs, supported increased sphere formation and clonogenic capabilities, and ultimately promoted a drug resistant phenotype in tissue culture [244-246]. miR-9 can also reduce apoptosis by lowering Caspase-3 expression and supporting proliferation elements such as Ki67 [198].

One challenge in the prostate cancer field is that some tumors have a differential dependence on androgen receptors to support growth and proliferation. However, this steroid hormone response is not as robust as it is in the mammary gland, resulting in more complex molecular heterogeneity with respect to cancer subtyping. We raise this point, because a different study indicated that miR-9 is significantly down-regulated in prostate cancer cell lines as compared to normal prostate cells [221]. Furthermore, miR-9 has been shown to target MEKK3, an oncogenic kinase that promotes cellular proliferation, migration, invasion, and EMT [221,247]. However, none of these studies have carefully assessed the abundance or activity of miR-9 variants in response to testosterone levels. It may very well be that certain miR-9 variants predominate under conditions of low androgen levels, which would result in a different repertoire of dysregulated mRNA targets that may either promote or inhibit tumorigenesis. Only in depth genetic

and mechanistic genetic studies can address these differential cellular mechanisms.

7.6 Gastric and Liver Cancers

Gastric cancer (GC) is a leading cause of cancer deaths in humans [248]. Studies show that miR-9 expression is significantly reduced in both GC cells and the plasma of GC patients as compared to normal healthy controls [222]. More specifically, miR-9 inhibits the migration and invasion of GC cells by targeting TNFAIP8L3. Furthermore, miR-9 binds to the 3' UTR of TNFAIP8L3 reducing its expression, and thereby reducing the aggressiveness of GC cells, as confirmed by transwell and wound-healing assays *in vitro* [196]. These studies suggest miR-9 is a putative tumor suppressor in gastric cancers. Additionally, it has been shown that miR-9 targets genes such as RAB34, cyclin D1, and Est1, all of which are involved in tumor progression and metastasis, and inhibit NF- κ B1, reducing tumor growth and invasion [223,224]. Finally, miR-9 downregulation also shows strong correlations to clinicopathological features of tumor progression in patients [225].

Upon further investigation it appears miR-9-5p is the miR-9 isoform driving this phenotype, with almost no data on the miR-9-3p variant. This is relevant, as miR-9-3p is expressed in stomach and liver tissues (see Figure 3), and therefore may have biological activity. In support of this, miR-9-3p appears to be elevated in liver cancer and targets the non-coding RNA HULC. This is a fascinating story because the elevated expression of miR-9 is not directly linked with the activity of miR-9. In fact, miR-9 directly targets myosin heavy chain 9 (MYH9), a gene linked to cancer metastasis. HULC acts as a sponge for miR-9, reducing its availability and consequently allowing for MYH9 to be expressed. This suggests that silencing HULC can inhibit gastric cancer progression by controlling the miR-9/MYH9 axis, opening a potential therapeutic window for this pathway by targeting HULC [226,249,250]. However, what has not been addressed in this study is if miR-9-3p becomes engaged with HULC, is there an accumulation of miR-9-5p variants? Furthermore, what are the regulatory effects miR-9 variants have on the tumorigenic process.

Another example of differential miR-9 activity in liver cancer involves the miR-9, CDX2 story. Here, miR-9 targets and suppresses the tumor suppressor genes CDX2 and CDH1 (i.e., E-cadherin) resulting in pro-oncogenic properties [251]. The use of LNA-modified AMOs, designed to target and bind to miR-9-5p, resulted in the elevated expression of CDH1 mRNA, and restoration of E-cadherin levels [252]. These findings again, suggest promising strategies for the direct therapeutic targeting of a miRNA variant. Here the targeting of miR-9-5p with LNA's blocks the function of miR-9-5p. Additionally, miR-9 could be used as a diagnostic tool for the management, identification, and prognosis of gastric cancer. Taken together, given the complex role of miR-9 in gastric cancer further research is needed to parse out the dual functionality of miR-9.

7.7 Leukemia

As discussed earlier, miR-9 was originally identified as a tumor suppressor in chronic lymphocytic leukemia (CLL). In fact, one of the miR-9 host genes is extensively hypermethylated in approximately 17% of patient samples [253]. This epigenetic silencing leads to decreased miR-9 expression, contributing to tumor progression. miR-9 targets and suppresses NF κ B1, a key activator of tumorigenesis through the promotion of cell proliferation and activation of anti-apoptotic genes (see Table 1). By downregulating NF κ B1, miR-9 limits tumor cell survival and reinforces its role as a tumor suppressor in CLL [228-230]. To further support this, treating CLL cells with 5-Aza-2'-deoxycytidine (5-AzaC), a DNA demethylating agent, restored miR-9 expression resulting in reduced NF κ B1 activity, and thus protumor-suppressive effects. While 5-AzaC is considered a crude therapeutic compound as it would result in many genes becoming de-methylated and re-activated, another approach may be to develop synthetic RNA oligonucleotide that could restore the function miR-9-5p variants, showcasing the therapeutic potential for miR-9 in CLL.

In the case of acute myeloid leukemia (AML), the expression of miR-9 is significantly downregulated, and the loss of miR-9 expression correlates with lower survival rates in AML patients [231,232]. The mechanism of action for miR-9 occurs through the direct binding and targeting of the CXCR4 3' UTR mRNA, resulting in reduced CXCR4 expression. CXCR4 is a crucial gene that supports AML cellular proliferation via extending the G1 phase of mitosis. CXCR4 also supports chemokine induced cell migration, as blood cells home to certain tissue regions based on the gradient of chemokine expression. The re-expression of miR-9 in AML results in G1 phase arrest and apoptosis, as well as stalled cellular migration. These findings highlight that the miR-9/CXCR4 axis function as a promising therapeutic target in AML.

What is not well understood though, is whether miR-9-5p or miR-9-3p would be the best candidate for a therapeutic in AML. This is because re-expression of the silenced miR-9-5p in AML cells targets the CXCR4 gene resulting in anti-tumorigenic phenotypes. However the silencing of miR-9 genetic loci in AML also means that miR-9-3p levels would also be reduced. However, there is no study that really assesses the levels of miR-9-3p, and/or determines whether miR-9-3p becomes elevated in AML. This is an important question, as there is evidence that miR-9-3p is overexpressed in MLL-rearranged type AML when compared to both normal controls and non-MLL-rearranged AML [190]. MLL-AF9 is probably one of the most common fusion proteins generated by chromosomal abnormalities and is the oncogenic driver in AML patients. For some unknown reason, miR-9-3p is expressed at elevated levels in MLL-AF9. miR-9 promotes leukemogenesis by suppressing expression of the transcription factors RHOH and RYBP, which are critical for normal hematopoiesis and apoptosis regulation [254]. Researchers have yet to

understand why miR-9-5p has a diminished role in MLL-AF9 AML. Perhaps there are differential levels of RNA editing that affect DICER recognition of the miRNA duplex. Taken together, these findings highlight that miR-9-3p is certainly a potential therapeutic target in MLL-AF9, while miR-9-5p may be a target in non-MLL-rearranged AML. Yet, more in-depth studies are required to determine which miR-9 isoforms predominate in these hematopoietic cancers. With this information, potent miR-9-5p or miR-9-3p decoy oligonucleotides could be developed so as to offer a promising treatment avenue for patients with aggressive leukemia subtypes that confer poor prognosis.

8. Therapeutic Delivery of Synthetically Modified MiR-9

Over the past decade the biochemistry supporting development of RNA-based therapeutics has advanced on many levels. These next-generation miRNA therapeutics still function by responding to complementary sequences in either a target miRNAs or candidate mRNAs. This is due to the fact that a number of modifications can be made to the backbone of the RNA oligonucleotide that facilitate cellular uptake, enhanced target duplex stability, and even result in the recruitment of specific RNA binding proteins to the miRNA targeting loci. In addition to these modifications, new delivery systems that involve miRNA packaging into exosomes and/or nanoparticles have paved the way for exponentially more intuitive RNA drug design for the oncological field.

As an example, in the case of brain cancer, miRNA therapeutics have been developed to function by re-expressing the lost activity of tumor suppressive miRNAs, and in other cases to sponge/decoy oncomiRs [255-259]. The development of these miRNA therapeutics has recently focused on enhancing the *in vivo* stability of RNA molecules and in designing precise delivery systems for tissue-specific release with minimal toxicity [260-264]. The limitations of these pre-clinical studies have been centered around the issue of effective delivery of these compounds to the anatomical regions where these tumor cells reside, as well as the concern of off-target effects of the RNA-oligonucleotide. Surprisingly, the common criticism of RNA therapy is that these oligonucleotides could bind other mRNA targets which could contribute to some side effects in patients. However, small drug kinase inhibitors are known to be promiscuous as well, given these drugs target the conserved ATPase pocket shared amongst almost all known protein kinases.

Another approach has therefore been to use the knowledge regarding a particular miRNA pathway and to then develop RNA oligonucleotides that interact with culprit mRNAs that operate as tumor suppressors or oncoproteins. This has been most apparent in the field of oncology. Specifically, in brain cancer, certain nanoformulations of a synthetic short-interfering RNA (siRNA) to TGF- β (a known target of certain miRNAs) have been developed to cross a synthetic blood-brain barrier in certain lab models [265-268]. From these

studies it appears the gene silencing efficiency of si-TGF- β enhances the cytotoxicity of temozolomide (TMZ) in glioblastoma cell lines. Additionally, Xu *et al.* developed a pH-responsive nanoplatform that delivers an siRNA directed against BRD4. First BRD4 is a well known miR-9 target, and secondly an siRNA directed to BRD4 has potent anti-tumorigenic effects by altering the local tumor microenvironment. The unique strategy of the si-BRD4 platform is that this nanoplatform consists of a PHMEMA core which responds to changes in pH present in the acidic tumor microenvironment, while containing a PEGylated outer shell to protect and maintain the RNA compound while being circulated within the blood. This PHMEMA technology therefore, results in enhanced therapeutic payloads being delivered to the anatomic locations where the tumor cells of interest reside.

These studies highlight challenges such as efficient RNA delivery, miRNA stability, and deleterious immune responses. Yet, given the evidence supporting the effectiveness and safety of clinically approved mRNA vaccines (i.e., COVID-19), coupled with growing interest in mRNA-based therapeutics, mRNA technology is poised to become one of the major pillars of cancer drug development. Because miRNA/mRNA therapeutics deliver synthetic RNA into cells to regulate protein expression, or therapeutically re-express proteins of interest, respectively, these compounds are actually a safer alternative to DNA-based therapies that integrate into the host genome (i.e., concern with viral based delivery systems). Clinical scientists have actually developed *in vitro* transcribed mRNA-based therapeutics for cancer treatment, which include the characteristics of the various synthetic mRNAs as well the packaging systems for efficient mRNA delivery [269-274]. Taken together, there are still current challenges remaining in the field, such as the need for improved delivery mechanisms and management of the patient immune response. Despite these hurdles, there is optimism about the future prospects of miRNA/mRNA-based therapies. It is anticipated that many promising mRNA-based treatments currently under investigation will eventually translate into clinical applications, ultimately benefiting patients by providing more effective and personalized therapeutic options.

9. The Role of MiR-9 in Drug Resistance

One of the most important areas of cancer research involves the issue of drug sensitivity and or drug response in the clinical setting. In many tumor settings, patients can either be initially responsive to certain therapies or completely refractory. Moreover, in certain contexts patients are living longer post cancer diagnosis and therefore are facing the challenges of acquired drug resistance resulting in limited options for extended treatments within these patients. As an example, in lung cancer, the leading cause of cancer-related deaths worldwide, a majority of patients that respond to cisplatin and radiation therapy eventually relapse. Clinicians have struggled to develop newer therapies for these patients. Recently, the aberrant expression of

certain miRNAs are now known to be associated with therapeutic resistance [275-279]. In the case of miR-9, A549 lung cancer cells expressing miR-9 resulted in radiosensitization. Furthermore, miR-9 also prevents A549 cells from migrating and proliferating efficiently. These studies have not fully interpreted the miR-9 isoforms involved, as well as the exact genetic mRNA targets that contribute to these phenotypes, therefore more work is required to elucidate this chemoresistant biology.

In the breast cancer setting, the role of miR-9 is more evident, yet more confounding. As mentioned above miR-9 can regulate both hormone responsiveness and receptor kinase pathways important in maintaining tumorigenesis. Despite these disparate responses, many still view miR-9 as an oncogenic miRNA that supports tumorigenesis. In support of this, in MCF-7 cells the exosomal transfer of miR-9-5p, as well as other miRNAs, enhanced the resistance of MCF-7 cells to tamoxifen [207,277]. The ability for miR-9-5p to target and downregulate ADIPOQ is quite relevant given adiponectin signaling is known to modulate AMPK and P38 MAPK signaling pathways that are known to support cytoprotection, glucose uptake, and fatty acid oxidation in the absence of hormone signaling. This indicates that specifically expressing a decoy miR-9-5p isoform in patients with acquired tamoxifen resistance may extend curative latency within these patients.

In other cancer types, the cellular mRNA repertoire completely changes depending upon the evolutionary bottleneck, caused by the chemotherapeutic action on the tumorigenic cell type. For instance in CLL, the use of adriamycin (ADR) results in initial cytotoxicity, yet these tumor cells typically express multi-drug transporters such as ABCB1 so as to prevent the ADR compound from operating on the tumor DNA [278]. Therefore an RNA therapy that targets ABCB1 may be a logical approach in re-sensitizing these cells to ADR. In glioblastoma, the agent of choice in the clinic for over thirty years is still TMZ [280], which results in an initial and robust apoptosis of glioma cells. Over time however, most gliomas become refractory to any chemotherapeutic agent utilized. Given the role of miR-9 in gliomagenesis, researchers should further assess if miR-9 alters the response of these tumors to TMZ. Interestingly, in clinical settings, the re-expression of miR-9 was sufficient to reverse cancer cell chemoresistance. This is true in the case of re-sensitizing ADR-resistant K562 CML cells to ADR, as well as increasing the apoptotic rate of glioma cells when simultaneously given TMZ, however, the target mRNA genes involved in this re-sensitization process are still too numerous to fully understand the genetic driver(s) of chemoresistance.

Many of these chemosensitization studies are still in the preliminary stages of development, and therefore few researchers have gone back to understand how various miR-9 isoforms regulate acquired drug resistance in their stable cancer cell models. In one study, researchers found that both miR-9-5p and miR-9-3p can actually target DNA topoisomerase II α (TOP2 α) [281]. TOP2 α is a decatenating enzyme that generates double stranded

DNA breaks during DNA repair. Tumor cells tend to down regulate this gene, allowing for genomic mutations to occur, facilitating tumorigenesis. Interestingly, both miR-9 variants can bind and target TOP2 α in leukemia, indicating the miR-9 loci operates as a *bona-fide* oncogene. More importantly, miR-9-5p and miR-9-3p become elevated when K562 cells are treated with etoposide. Furthermore, the transfection of synthetic miR-9-3p or miR-9-5p inhibitors in etoposide-resistant K562 cells resulted in enhanced etoposide-induced DNA damage and increased TOP2 α protein levels. These studies emphasize the importance of the cellular context of a particular cancer, and the cell-specific miRNA and mRNA repertoire present after acquired drug resistance. When these intricacies are fully understood, effective therapeutic strategies can be employed that utilize synthetic miRNA oligonucleotides so as to effectively alter the cellular mRNA repertoire, such that drug resistance cells can become re-sensitized to chemotherapeutic compounds that are considered safe, and effective as determined by clinical standards.

10. Conclusion

The story of miR-9 showcases the inherent duality of miRNA functionality, acting as both a tumor suppressor and an oncogene across various cancers. The role of miR-9 is highly context-dependent, and is shaped by the specific genetic, epigenetic, and molecular environments of these different tumor types. As a tumor suppressor, miR-9 is downregulated through mechanisms such as hypermethylation, resulting in the ability of oncogenic pathways controlled by miR-9 to be activated, resulting in cancer development. Furthermore, miR-9 overexpression can at times promote tumorigenesis by suppressing key tumor suppressors in malignancies such as MLL-rearranged acute myeloid leukemia and glioma. Interestingly, miR-9 can also operate as an oncogene in some cancers through targeting genes that support acquired drug resistance. The dual role of miR-9 is in part explained by the differential cellular mRNAs that predominate in the cell at any given point in time, but also by the two major miR-9 variants miR-9-5p and miR-9-3p being differentially co-expressed in these cells, each with vastly different cellular mRNA targets. However, additional miR-9 variants exist, and highlights the molecular complexity of miR-9 and the further necessity to elucidate the mechanism of action with respect to miR-9 as a therapeutic agent. Importantly, development of miR-9-based therapies—whether through restoring expression in cancers where miR-9 functions as a tumor suppressor, or inhibiting function in cancers where miR-9 behaves as an oncogene—offers a promising option for precision oncology. While significant advancements have been made in understanding the role of miR-9, further research is needed to overcome the delivery, stability, and specificity challenges associated with miRNA therapeutics. By enhancing our knowledge of miR-9 biology, researchers can use miR-9 as a diagnostic marker and therapeutic target, leading to novel cancer treatments tailored to the molecular profile of patients.

Ethical Approval

Not applicable in this study.

Funding Support

The work is partially supported by The Brain Institute of America.

Consent to Publish

Authors give their consent to publish this manuscript upon acceptance.

Conflict of Interest

Authors declare no conflict of interest.

Author Contributions

M.I., M.A., A.A., E.S., and B.A. performed the literature research and co-wrote the manuscript. G.S., J.I., N.R., and H.D. provided conceptual editing support, and developed the figures and tables for the manuscript. L.G., Z.F., A.P., Y.C., and B.A. reviewed and editorially revised the manuscript. B.A. reviewed and provided advice on the content of this manuscript.

References

- [1] Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. *Nature Reviews Cancer*. 2006, 6(4), 259-269. DOI: 10.1038/nrc1840
- [2] Garzon R, Calin GA, Croce CM. MicroRNAs in Cancer. *Annual Review of Medicine*. 2009, 60, 167-179. DOI: 10.1146/annurev.med.59.053006.104707
- [3] Croce CM. *Oncogenes and Cancer*. *New England Journal of Medicine*. 2008, 358, 502-511. DOI: 10.1056/NEJMra072367
- [4] Adams BD, Kasinski AL, Slack FJ. Aberrant Regulation and Function of MicroRNAs in Cancer. *Current Biology*. 2014, 24(16), R762-76. DOI: 10.1016/j.cub.2014.06.043
- [5] Kuhn DE, Martin MM, Feldman DS, Terry AV, Nuovo GJ, et al. Experimental validation of miRNA targets. *Methods*. 2008, 44(1), 47-54. DOI: 10.1016/j.ymeth.2007.09.005
- [6] Bartel DP. MicroRNAs: Genomics, Biogenesis, Mechanism, and Function. *Cell*. 2004, 116(2), 281-297. DOI: 10.1016/S0092-8674(04)00045-5
- [7] Bartel DP. MicroRNAs: Target Recognition and Regulatory Functions. *Cell*. 2009, 136(2), 215-233. DOI: 10.1016/j.cell.2009.01.002
- [8] Friedman RC, Farh KKH, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. *Genome Research*. 2009, 19(1), 92-105. DOI: 10.1101/gr.082701.108
- [9] Hu CX, Cao YB, Li P, Tang XR, Yang MH, et al. Oleanolic Acid Induces Autophagy and Apoptosis via the AMPK-mTOR Signaling Pathway in Colon Cancer. *Journal of Oncology*. 2021, 8281718. DOI: 10.1155/2021/8281718
- [10] Zhang XM, Yu SS, Li XB, Wen XX, Liu S, et al. Research progress on the interaction between oxidative stress and platelets: Another avenue for cancer? *Pharmacological Research*. 2023, 191, 106777. DOI: 10.1016/j.phrs.2023.106777
- [11] Guo WW, Qiao TY, Li T. The role of stem cells in small-cell lung cancer: Evidence from chemoresistance to immunotherapy. *Seminars in Cancer Biology*. 2022, 87, 160-169. DOI: 10.1016/j.semcancer.2022.11.006
- [12] Guo Q, Li D, Luo XY, Yuan Y, Li T, et al. The Regulatory Network and Potential Role of LINC00973-miRNA-mRNA ceRNA in the Progression of Non-Small-Cell Lung Cancer. *Frontiers in Immunology*. 2021, 12, 684807. DOI: 10.3389/fimmu.2021.684807
- [13] Sinclair PB, Harrison CJ, Jarosová M, Foroni L. Analysis of balanced rearrangements of chromosome 6 in acute leukemia: Clustered breakpoints in q22-q23 and possible involvement of c-MYB in a new recurrent translocation, t(6;7)(q23;q32-36). *Haematologica*. 2005, 90(5), 602-611. DOI: 10.1182/blood.V104.11.2893.2893
- [14] Melo SA, Esteller M. Dysregulation of microRNAs in cancer: Playing with fire. *FEBS Letters*. 2011, 585(13), 2087-99. DOI: 10.1016/j.febslet.2010.08.009
- [15] Wiemer EAC. The role of microRNAs in cancer: No small matter. *European Journal of Cancer*. 2007, 43(10), 1529-1544. DOI: 10.1016/j.ejca.2007.04.002
- [16] Izumiya M, Okamoto K, Tsuchiya N, Nakagama H. Functional screening using a microRNA virus library and microarrays: A new high-throughput assay to identify tumor-suppressive microRNAs. *Carcinogenesis*. 2010, 31(8), 1354-1359. DOI: 10.1093/carcin/bgq112
- [17] Fan MY, Krutilina R, Sun J, Sethuraman A, Yang CH, et al. Comprehensive analysis of microRNA (miRNA) targets in breast cancer cells. *The Journal of Biological Chemistry*. 2013, 288(38), 27480-93. DOI: 10.1074/jbc.M113.491803
- [18] Ciafrè SA, Galardi S, Mangiola A, Ferracin M, Liu CG, et al. Extensive modulation of a set of microRNAs in primary glioblastoma. *Biochemical and Biophysical Research Communications*. 2005, 334(4), 1351-1358. DOI: 10.1016/j.bbrc.2005.07.030
- [19] Baer C, Claus R, Plass C. Genome-wide epigenetic regulation of miRNAs in cancer. *Cancer Research*. 2013, 73(2), 473-477. DOI: 10.1158/0008-5472.CAN-12-3731
- [20] Zhao XL, Xiao ZH, Li B, Li HW, Yang B, et al. miRNA-21 may serve as a promising noninvasive marker of glioma with a high diagnostic performance: a pooled analysis of 997 patients. *Therapeutic Advances in Medical Oncology*. 2021, 13, 1758835920987650. DOI: 10.1177/1758835920987650
- [21] Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. *Proceedings of the National Academy of Sciences of the United States of America*. 2006, 103(7), 2257-61. DOI: 10.1073/pnas.0510565103
- [22] O'Brien J, Hayder H, Zayed Y, Peng C. Overview of microRNA biogenesis, mechanisms of actions, and circulation. *Frontiers in Endocrinology*. 2018, 9, 402. DOI: 10.3389/fendo.2018.00402
- [23] Adams BD, Furneaux H, White BA. The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines. *Molecular Endocrinology*. 2007, 21(5), 1132-1147. DOI: 10.1210/me.2007-0022
- [24] Peng Y, Croce CM. The role of MicroRNAs in human cancer. *Signal transduction and targeted therapy*. 2016, 1, 15004. DOI: 10.1038/sigtrans.2015.4
- [25] Chua FY, Adams BD. Androgen receptor and miR-206 regulation in prostate cancer. *Transcription*. 2017, 8(5), 313-327. DOI: 10.1080/21541264.2017.1322668
- [26] Calin GA, Ferracin M, Cimmino A, Di-Leva G, Shimizu M, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic

- leukemia. *The New England Journal of Medicine*. 2005, 353(17), 1793-1801. DOI: 10.1056/NEJMoa050995
- [27] Calin GA, Croce CM. MicroRNA signatures in human cancers. *Nature Reviews Cancer*. 2006, 6(11), 857-866. DOI: 10.1038/nrc1997
- [28] Croce CM, Calin GA. miRNAs, cancer, and stem cell division. *Cell*. 2005, 122(1), 6-7. DOI: 10.1016/j.cell.2005.06.036
- [29] Marcucci G, Maharry K, Radmacher MD, Mrózek K, Vukosavljevic T, et al. Prognostic significance of, and gene and MicroRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: A cancer and leukemia group B study. *Journal of Clinical Oncology*. 2008, 26(31), 5078-5087. DOI: 10.1200/JCO.2008.17.5554
- [30] Gonzalez-Martin A, Adams BD, Lai MY, Shepherd J, Salvador-Bernaldez M, et al. The microRNA miR-148a functions as a critical regulator of B cell tolerance and autoimmunity. *Nature Immunology*. 2016, 17(4), 433-440. DOI: 10.1038/ni.3385
- [31] Zhang DS, Li YY, Chen XJ, Li YJ, Liu ZY, et al. BCL2 promoter methylation and miR-15a/16-1 upregulation is associated with sanguinarine-induced apoptotic death in rat HSC-T6 cells. *Journal of Pharmacological Sciences*. 2015, 127(1), 135-44. DOI: 10.1016/j.jphs.2014.11.012
- [32] Diniz MG, Gomes CC, De-Castro WH, Guimarães ALS, De-Paula AMB, et al. MiR-15a/16-1 influences BCL2 expression in keratocystic odontogenic tumors. *Cellular Oncology*. 2012, 35(4), 285-91. DOI: 10.1007/s13402-012-0087-3
- [33] Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. *Proceedings of the National Academy of Sciences of the United States of America*. 2005, 102(39), 13944-9. DOI: 10.1073/pnas.0506654102
- [34] Pekarsky Y, Balatti V, Croce CM. BCL2 and miR-15/16: From gene discovery to treatment. *Cell Death and Differentiation*. 2018, 25(1), 21-26. DOI: 10.1038/cdd.2017.159
- [35] Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, et al. MicroRNAs in body fluids-the mix of hormones and biomarkers. *Nature Reviews Clinical Oncology*. 2011, 8(8), 467-477. DOI: 10.1038/nrclinonc.2011.76
- [36] Heneghan HM, Miller N, Kerin MJ. MiRNAs as biomarkers and therapeutic targets in cancer. *Current Opinion in Pharmacology*. 2010, 10(5), 543-550. DOI: 10.1016/j.coph.2010.05.010
- [37] Moro-Soria A. MicroRNAs as biomarkers and therapeutic targets in cancer. *Biotechnologia Aplicada*. 2014, 31(2), 87-92. DOI: 10.1016/j.trsl.2011.01.013
- [38] Adams BD, Arem H, Hubal MJ, Cartmel B, Li FY, et al. Exercise and weight loss interventions and miRNA expression in women with breast cancer. *Breast Cancer Research and Treatment*. 2018, 170(1), 55-67. DOI: 10.1007/s10549-018-4738-6
- [39] Ha MJ, Kim VN. Regulation of microRNA biogenesis. *Nature Reviews Molecular Cell Biology*. 2014, 15, 509-524. DOI: 10.1038/nrm3838
- [40] Lee YT, Ahn CY, Han JJ, Choi HJ, Kim JW, et al. The nuclear RNase III Drosha initiates microRNA processing. *Nature*. 2003, 425(6956), 415-419. DOI: 10.1038/nature01957
- [41] Winter J, Jung S, Keller S, Gregory RI, Diederichs S. Many roads to maturity: microRNA biogenesis pathways and their regulation. *Nature Cell Biology*. 2009, 11(3), 228-34. DOI: 10.1038/ncb0309-228
- [42] Yang JS, Lai EC. Alternative miRNA Biogenesis Pathways and the Interpretation of Core miRNA Pathway Mutants. *Molecular Cell*. 2011, 43(6), 892-903. DOI: 10.1016/j.molcel.2011.07.024
- [43] Du TT, Zamore PD. Beginning to understand microRNA function. *Cell Research*. 2007, 17(8), 661-663. DOI: 10.1038/cr.2007.67
- [44] MacFarlane LA, Murphy PR. MicroRNA: Biogenesis, Function and Role in Cancer. *Current Genomics*. 2010, 11(7), 537-561. DOI: 10.2174/138920210793175895
- [45] Yang JS, Lai EC. Dicer-independent, Ago2-mediated microRNA biogenesis in vertebrates. *Cell Cycle*. 2010, 9(22), 4455-4460. DOI: 10.4161/cc.9.22.13958
- [46] Chendrimada TP, Gregory RI, Kumaraswamy E, Norman J, Cooch N, et al. TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. *Nature*. 2005, 436(7051), 740-744. DOI: 10.1038/nature03868
- [47] Kurihara Y, Watanabe Y. Processing of miRNA precursors. *Methods in Molecular Biology*. 2010, 592, 231-41. DOI: 10.1007/978-1-60327-005-2_15
- [48] Gao M, Wei W, Li MM, Wu YS, Ba ZQ, et al. Ago2 facilitates Rad51 recruitment and DNA double-strand break repair by homologous recombination. *Cell Research*. 2014, 24(5), 532-541. DOI: 10.1038/cr.2014.36
- [49] Lee SR, Collins K. Two classes of endogenous small RNAs in *Tetrahymena thermophila*. *Genes & Development*. 2006, 20(1), 28-33. DOI: 10.1101/gad.1377006
- [50] Chen Q, Zhou T. Emerging functional principles of tRNA-derived small RNAs and other regulatory small RNAs. *Journal of Biological Chemistry*. 2023, 299(10), 105225. DOI: 10.1016/j.jbc.2023.105225
- [51] Wang HB, Gao Y, Guo JY. Comprehensive analysis of Dicer-like, Argonaute, and RNA-dependent RNA polymerase gene families and their expression analysis in response to abiotic stresses in *Jatropha curcas*. *Journal of Plant Interactions*. 2024, 19(1). DOI: 10.1080/17429145.2023.2282432
- [52] Kocic G, Hadzi-Djokic J, Colic M, Veljkovic A, Tomovic K, et al. The Role of Nucleases Cleaving TLR3, TLR7/8 and TLR9 Ligands, Dicer RNase and miRNA/piRNA Proteins in Functional Adaptation to the Immune Escape and Xenophagy of Prostate Cancer Tissue. *International Journal of Molecular Sciences*. 2023, 24(1), 509. DOI: 10.3390/ijms24010509
- [53] Nakanishi K. When Argonaute takes out the ribonuclease sword. *Journal of Biological Chemistry*. 2024, 300(1), 105499. DOI: 10.1016/j.jbc.2023.105499
- [54] Flynt AS, Greimann JC, Chung WJ, Lima CD, Lai EC. MicroRNA Biogenesis via Splicing and Exosome-Mediated Trimming in *Drosophila*. *Molecular Cell*. 2010, 38(6), 900-7. DOI: 10.1016/j.molcel.2010.06.014
- [55] Butkytė S, Čiupas L, Jakubauskienė E, Vilys L, Mocevičius P, et al. Splicing-dependent expression of microRNAs of mirtron origin in human digestive and excretory system cancer cells. *Clinical Epigenetics*. 2016, 8, 33. DOI: 10.1186/s13148-016-0200-y
- [56] Westholm JO, Lai EC. Mirtrons: MicroRNA biogenesis via splicing. *Biochimie*. 2011, 93(11), 1897-904. DOI: 10.1016/j.biochi.2011.06.017
- [57] Pawlina-Tyszko K, Szmatoła T. Benchmarking of bioinformatics tools for NGS-based microRNA profiling with RT-qPCR method. *Functional & Integrative Genomics*. 2023, 23(4), 347. DOI: 10.1007/s10142-023-01276-w
- [58] Vasconcelos AM, Carmo MB, Ferreira B, Viegas I, Gama-Carvalho M, et al. IsomiR_Window: a system for analyzing small-RNA-seq data in an integrative and user-friendly manner. *BMC Bioinformatics*. 2021, 22(1), 37. DOI: 10.1186/s12859-021-03955-6

- [59] Nersisyan S, Gorbonos A, Makhonin A, Zhiyanov A, Shkurnikov M, et al. isomiRTar: a comprehensive portal of pan-cancer 50-isomiR targeting. *PeerJ*. 2022, 10, e14205. DOI: 10.7717/peerj.14205
- [60] Moradi A, Whatmore P, Farashi S, Barrero RA, Batra J. IsomiR-eQTL: A Cancer-Specific Expression Quantitative Trait Loci Database of miRNAs and Their Isoforms. *International Journal of Molecular Sciences*. 2022, 23(20), 12493. DOI: 10.3390/ijms232012493
- [61] Nersisyan S, Zhiyanov A, Engibaryan N, Maltseva D, Tonevitsky A. A novel approach for a joint analysis of isomiR and mRNA expression data reveals features of isomiR targeting in breast cancer. *Frontiers in Genetics*. 2022, 13, 1070528. DOI: 10.3389/fgene.2022.1070528
- [62] Ameres SL, Zamore PD. Diversifying microRNA sequence and function. *Nature Reviews Molecular Cell Biology*. 2013, 14(8), 475-88. DOI: 10.1038/nrm3611
- [63] Gibbins DJ, Ciaudo C, Erhardt M, Voynet O. Multivesicular bodies associate with components of miRNA effector complexes and modulate miRNA activity. *Nature Cell Biology*. 2009, 11(9), 1143-1149. DOI: 10.1038/ncb1929
- [64] Fabian MR, Sonenberg N, Filipowicz W. Regulation of mRNA Translation and Stability by microRNAs. *Annual Review of Biochemistry*. 2010, 79, 351-379. DOI: 10.1146/annurev-biochem-060308-103103
- [65] McKenzie AJ, Hoshino D, Hong NH, Cha DJ, Franklin JL, et al. KRAS-MEK Signaling Controls Ago2 Sorting into Exosomes. *Cell Reports*. 2016, 15(5), 978-987. DOI: 10.1016/j.celrep.2016.03.085
- [66] Hwang HW, Wentzel EA, Mendell JT. A Hexanucleotide Element Directs MicroRNA Nuclear Import. *Science*. 2007, 315(5808), 97-100. DOI: 10.1126/science.1136235
- [67] Kim CK, Linscott ML, Flury S, Zhang MJ, Newby ML, et al. 17 β -estradiol regulates mir-9-5p and mir-9-3p stability and function in the aged female rat brain. *Non-coding RNA*. 2021, 7(3), 53. DOI: 10.3390/ncrna7030053
- [68] Xian X, Cai LL, Li Y, Wang RC, Xu YH, et al. Neuron secrete exosomes containing miR-9-5p to promote polarization of M1 microglia in depression. *Journal of Nanobiotechnology*. 2022, 20(1), 122. DOI: 10.1186/s12951-022-01332-w
- [69] Keller S, Sanderson MP, Stoeck A, Altevogt P. Exosomes: From biogenesis and secretion to biological function. *Immunology Letters*. 2006, 107(2), 102-108. DOI: 10.1016/j.imlet.2006.09.005
- [70] Wittmann J, Jäck HM. Serum microRNAs as powerful cancer biomarkers. *Biochimica et Biophysica Acta*. 2010, 1806(2), 200-207. DOI: 10.1016/j.bbcan.2010.07.002
- [71] Russo F, Di-Bella S, Nigita G, Macca V, Laganà A, et al. miRandola: Extracellular Circulating MicroRNAs Database. *PLoS One*. 2012, 7(10), e47786. DOI: 10.1371/journal.pone.0047786
- [72] Ziętara KJ, Lejman J, Wojciechowska K, Lejman M. The Importance of Selected Dysregulated microRNAs in Diagnosis and Prognosis of Childhood B-Cell Precursor Acute Lymphoblastic Leukemia. *Cancers*. 2023, 15(2), 428. DOI: 10.3390/cancers15020428
- [73] Siouning AS, Seong TS, Kondo H, Bhassu S. MicroRNA Regulation in Infectious Diseases and Its Potential as a Biosensor in Future Aquaculture Industry: A Review. *Molecules*. 2023, 28(11), 4357. DOI: 10.3390/molecules28114357
- [74] Soheilifar MH, Nobari S, Hakimi M, Adel B, Masoudi-Khoram N, et al. Current concepts of microRNA-mediated regulatory mechanisms in human pulp tissue-derived stem cells: a snapshot in the regenerative dentistry. *Cell and Tissue Research*. 2023, 393(2), 229-251. DOI: 10.1007/s00441-023-03792-4
- [75] Mullen M, Williams K, LaRocca T, Duke V, Hambright WS, et al. Mechanical strain drives exosome production, function, and miRNA cargo in C2C12 muscle progenitor cells. *Journal of Orthopaedic Research*. 2023, 41(6), 1186-1197. DOI: 10.1002/jor.25467
- [76] Bravo-Vázquez LA, Frías-Reid N, Ramos-Delgado AG, Osorio-Pérez SM, Zlotnik-Chávez HR, et al. MicroRNAs and long non-coding RNAs in pancreatic cancer: From epigenetics to potential clinical applications. *Translational Oncology*. 2023, 27, 101579. DOI: 10.1016/j.tranon.2022.101579
- [77] Dong X, Xing JB, Liu QC, Ye M, Zhou Z, et al. CircPLXNA2 Affects the Proliferation and Apoptosis of Myoblast through circPLXNA2/gga-miR-12207-5P/MDM4 Axis. *International Journal of Molecular Sciences*. 2023, 24(6), 5459. DOI: 10.3390/ijms24065459
- [78] Alieva AM, Teplova NV, Reznik EV, Baikova IE, Akhmedova MF, et al. Current insights into the role of miRNA-125 in cardiovascular disease: potential biological markers and therapeutic targets. *Medical Journal of the Russian Federation*. 2023, 29(4), 311-324. DOI: 10.17816/medjrf112141
- [79] Nassiri SM, Ahmadi-Afshar N, Almasi P. Insight into microRNAs' involvement in hematopoiesis: current standing point of findings. *Stem Cell Research & Therapy*. 2023, 14(1), 282. DOI: 10.1186/s13287-023-03504-3
- [80] Nasrolahi A, Azizidoost S, Radoszkiewicz K, Najafi S, Ghaedrahmati F, et al. Signaling pathways governing glioma cancer stem cells behavior. *Cellular Signalling*. 2023, 101, 110493. DOI: 10.1016/j.cellsig.2022.110493
- [81] Hasani F, Masrouf M, Jazi K, Ahmadi P, Hosseini SS, et al. MicroRNA as a potential diagnostic and prognostic biomarker in brain gliomas: a systematic review and meta-analysis. *Frontiers in Neurology*. 2024, 15, 1357321. DOI: 10.3389/fneur.2024.1357321
- [82] Tluli O, Al-Maadhadi M, Al-Khulaifi AA, Akomolafe AF, Al-Kuwari SY, et al. Exploring the Role of microRNAs in Glioma Progression, Prognosis, and Therapeutic Strategies. *Cancers*. 2023, 15(17), 4213. DOI: 10.3390/cancers15174213
- [83] Jegathesan Y, Stephen PP, Sati ISEE, Narayanan P, Monif M, et al. MicroRNAs in adult high-grade gliomas: Mechanisms of chemotherapeutic resistance and their clinical relevance. *Biomedicine and Pharmacotherapy*. 2024, 172, 116277. DOI: 10.1016/j.biopha.2024.116277
- [84] Liu L, Zhu ZQ, Li X, Zheng Y. DNA methylation-induced ablation of miR-133a accelerates cancer aggressiveness in glioma through upregulating peroxisome proliferator-activated receptor γ . *SLAS Discovery*. 2023, 28(1), 19-28. DOI: 10.1016/j.slasd.2022.08.004
- [85] Wang G, Yang XX, Qi M, Li M, Dong M, et al. Systematic analysis identifies REST as an oncogenic and immunological biomarker in glioma. *Scientific Reports*. 2023, 13(1), 3023. DOI: 10.1038/s41598-023-30248-0
- [86] Makowska M, Smolarz B, Romanowicz H. microRNAs (miRNAs) in Glioblastoma Multiforme (GBM)-Recent Literature Review. *International Journal of Molecular Sciences*. 2023, 24(4), 3521. DOI: 10.3390/ijms24043521
- [87] Beylerli O, Shi HZ, Begliarzade S, Shumadalova A, Ilyasova T, et al. MiRNAs as new potential biomarkers and therapeutic targets in brain metastasis. *Non-coding RNA Research*. 2024, 9(3), 678-686. DOI: 10.1016/j.ncrna.2024.02.014
- [88] Sufianov A, Begliarzade S, Ilyasova T, Liang YC, Beylerli O. MicroRNAs as prognostic markers and therapeutic targets in gliomas. *Non-coding RNA Research*. 2022, 7(3), 171-177. DOI: 10.1016/j.ncrna.2022.07.001

- [89] Nikolova E, Laleva L, Milev M, Spiriev T, Stoyanov S, et al. miRNAs and related genetic biomarkers according to the WHO glioma classification: From diagnosis to future therapeutic targets. *Non-coding RNA Research*. 2024, 9(1), 141-152. DOI: 10.1016/j.ncrna.2023.10.003
- [90] Kciuk M, Yahya EB, Mohamed MMI, Abdulsamad MA, Allaq AA, et al. Insights into the Role of LncRNAs and miRNAs in Glioma Progression and Their Potential as Novel Therapeutic Targets. *Cancers*. 2023, 15(13), 3298. DOI: 10.3390/cancers15133298
- [91] Gilyazova I, Ivanova E, Pavlov V, Khasanova G, Khasanova A, et al. Exosomal miRNA-155 and miRNA-146a are promising prognostic biomarkers of the severity of hemorrhagic fever with renal syndrome. *Non-coding RNA Research*. 2022, 8(1), 75-82. DOI: 10.1016/j.ncrna.2022.10.003
- [92] Gareev I, Beylerli O, Tamrazov R, Ilyasova T, Shumadalova A, et al. Methods of miRNA delivery and possibilities of their application in neuro-oncology. *Non-coding RNA Research*. 2023, 8(4), 661-674. DOI: 10.1016/j.ncrna.2023.10.002
- [93] Sufianov A, Beilerli A, Kudriashov V, Ilyasova T, Liang YC, et al. The role of long non-coding RNAs in the development of adipose cells. *Non-coding RNA Research*. 2023, 8(2), 255-262. DOI: 10.1016/j.ncrna.2023.02.009
- [94] Lee Y, Kim M, Han J, Yeom K, Lee S, et al. MicroRNA genes are transcribed by RNA polymerase II. *The EMBO Journal*. 2004, 23(20), 4051-60. DOI: 10.1038/sj.emboj.7600385
- [95] Yao YZ, Li YZ, Zhu XY, Zhao CG, Yang LH, et al. The emerging role of the piRNA/PIWI complex in respiratory tract diseases. *Respiratory Research*. 2023, 24(1), 76. DOI: 10.1186/s12931-023-02367-9
- [96] Xiao Y, Liu TM, MacRae IJ. A tiny loop in the Argonaute PIWI domain tunes small RNA seed strength. *The EMBO Journal*. 2023, 24(6), e55806. DOI: 10.15252/embr.202255806
- [97] Wang LL, Song XW, Gu LF, Li X, Cao SY, et al. NOT2 Proteins promote polymerase II-dependent transcription and interact with multiple microRNA biogenesis factors in Arabidopsis. *Plant Cell*. 2013, 25(2), 715-27. DOI: 10.1105/tpc.112.105882
- [98] Jiang GL, Reiter JL, Dong CP, Wang Y, Fang F, et al. Genetic Regulation of Human isomiR Biogenesis. *Cancers*. 2023, 15(17), 4411. DOI: 10.3390/cancers15174411
- [99] Han J, Mendell JT. MicroRNA turnover: a tale of tailing, trimming, and targets. *Trends in Biochemical Sciences*. 2023, 48(1), 26-39. DOI: 10.1016/j.tibs.2022.06.005
- [100] Cifuentes D, Xue HL, Taylor DW, Patnode H, Mishima Y, et al. A novel miRNA processing pathway independent of dicer requires argonaute2 catalytic activity. *Science*. 2010, 328(5986), 1694-8. DOI: 10.1126/science.1190809
- [101] Lee YY, Kim H, Kim VN. Sequence determinant of small RNA production by DICER. *Nature*. 2023, 615(7951), 323-330. DOI: 10.1038/s41586-023-05722-4
- [102] Shortridge MD, Chaubey B, Zhang HJ, Pavelitz T, Vidadala V, et al. Drug-Like Small Molecules That Inhibit Expression of the Oncogenic MicroRNA-21. *ACS Chemical Biology*. 2023, 18(2), 237-250. DOI: 10.1021/acscchembio.2c00502
- [103] Zhang HL, Lu RH, Huang JY, Li L, Cao YT, et al. N4-acetylcytidine modifies primary microRNAs for processing in cancer cells. *Cellular and Molecular Life Sciences: CMLS*. 2024, 81(1), 73. DOI: 10.1007/s00018-023-05107-w
- [104] Dadhwal G, Samy H, Bouvette J, El-Azzouzi F, Dagenais P, et al. Substrate promiscuity of Dicer toward precursors of the let-7 family and their 3'-end modifications. *Cellular and Molecular Life Sciences: CMLS*. 2024, 81(1), 53. DOI: 10.1007/s00018-023-05090-2
- [105] Lee YY, Lee H, Kim H, Kim VN, Roh SH. Structure of the human DICER-pre-miRNA complex in a dicing state. *Nature*. 2023, 615(7951), 331-338. DOI: 10.1038/s41586-023-05723-3
- [106] Steeman TJ, Weiner AMJ, David AP, Binolfi A, Calcaterra NB, et al. G-Quadruplexes Regulate miRNA Biogenesis in Live Zebrafish Embryos. *International Journal of Molecular Sciences*. 2023, 24(5), 4828. DOI: 10.3390/ijms24054828
- [107] Jaganathan D, Rajakani R, Doddamani D, Saravanan D, Pulipati S, et al. A conserved SNP variation in the pre-miR396c flanking region in *Oryza sativa indica* landraces correlates with mature miRNA abundance. *Scientific Reports*. 2023, 13(1), 2195. DOI: 10.1038/s41598-023-28836-1
- [108] Le TNY, Nguyen TA. High-throughput protocol for studying pri-miRNA processing using randomized sequences. *STAR Protocols*. 2024, 5(1), 102782. DOI: 10.1016/j.xpro.2023.102782
- [109] Ye XH, Yang Y, Yao JY, Wang M, Liu YX, et al. Nuclear receptor RXR α binds the precursor of miR-103 to inhibit its maturation. *BMC Biology*. 2023, 21(1), 197. DOI: 10.1186/s12915-023-01701-3
- [110] Larivera S, Neumeier J, Meister G. Post-transcriptional gene silencing in a dynamic RNP world. *Biological Chemistry*. 2023, 404(11-12), 1051-1067. DOI: 10.1515/hsz-2023-0203
- [111] Le CT, Nguyen TD, Nguyen TA. Two-motif model illuminates DICER cleavage preferences. *Nucleic Acids Research*. 2024, 52(4), 1860-1877. DOI: 10.1093/nar/gkad1186
- [112] Vilimova M, Pfeffer S. Post-transcriptional regulation of polycistronic microRNAs. *Wiley Interdisciplinary Reviews. RNA*. 2023, 14(2), e1749. DOI: 10.1002/wrna.1749
- [113] Yıldız A, Hasani A, Hempel T, Köhl N, Beicht A, et al. Trans-amplifying RNA expressing functional miRNA mediates target gene suppression and simultaneous transgene expression. *Molecular Therapy. Nucleic Acids*. 2024, 35(2), 102162. DOI: 10.1016/j.omtn.2024.102162
- [114] Yu AM. Role of microRNAs in the regulation of drug metabolism and disposition. *Expert Opinion on Drug Metabolism and Toxicology*. 2009, 5(12), 1513-28. DOI: 10.1517/17425250903307448
- [115] Chimenti C, Magnocavallo M, Vetta G, Alfarano M, Manguso G, et al. The Role of MicroRNA in the Myocarditis: a Small Actor for a Great Role. *Current Cardiology Reports*. 2023, 25(7), 641-648. DOI: 10.1007/s11886-023-01888-5
- [116] Szakats S, McAtamney A, Wilson MJ. Identification of novel microRNAs in the embryonic mouse brain using deep sequencing. *Molecular and Cellular Biochemistry*. 2024, 479(2), 297-311. DOI: 10.1007/s11010-023-04730-2
- [117] Wang YR, Tang XL, Lu J. Convergent and divergent evolution of microRNA-mediated regulation in metazoans. *Biological Reviews of the Cambridge Philosophical Society*. 2024, 99(2), 525-545. DOI: 10.1111/brv.13033
- [118] Chithung TA, Kansal S, Jajo R, Balyan S, Raghuvanshi S. Understanding the evolution of miRNA biogenesis machinery in plants with special focus on rice. *Functional & Integrative Genomics*. 2023, 23(1), 30. DOI: 10.1007/s10142-022-00958-1
- [119] Son S, Kim B, Yang J, Kim VN. Role of the proline-rich disordered domain of DROSHA in intronic microRNA processing. *Genes & Development*. 2023, 37(9-10), 383-397. DOI: 10.1101/gad.350275.122

- [120] Zhang Y, Yun Z, Gong L, Qu HX, Duan XW, et al. Comparison of miRNA Evolution and Function in Plants and Animals. *MicroRNA*. 2018, 7(1), 4-10. DOI: 10.2174/2211536607666180126163031
- [121] Cuperus JT, Fahlgren N, Carrington JC. Evolution and functional diversification of MIRNA genes. *Plant Cell*. 2011, 23(2), 431-42. DOI: 10.1105/tpc.110.082784
- [122] Ambros V. The functions of animal microRNAs. *Nature*. 2004, 431(7006), 350-5. DOI: 10.1038/nature02871
- [123] Bağcı Ö, Marzioğlu-özdemir E, Şanlıtürk B. Variant analysis of MiRNA regulatory genes in colorectal cancer. *Journal of Health Sciences and Medicine*. 2024, 7(1), 98-104. DOI: 10.32322/jhsm.1403868
- [124] Shang R, Lai EC. Parameters of clustered suboptimal miRNA biogenesis. *Proceedings of the National Academy of Sciences of the United States of America*. 2023, 120(41), e2306727120. DOI: 10.1073/pnas.2306727120
- [125] Szelągowski A, Kozakiewicz M. A Glance at Biogenesis and Functionality of MicroRNAs and Their Role in the Neuropathogenesis of Parkinson's Disease. *Oxidative Medicine and Cellular Longevity*. 2023, 2023, 7759053. DOI: 10.1155/2023/7759053
- [126] Ricarte-Filho JC, Casado-Medrano V, Reichenberger E, Spangler Z, Scheerer M, et al. DICER1 RNase IIIb domain mutations trigger widespread miRNA dysregulation and MAPK activation in pediatric thyroid cancer. *Frontiers in Endocrinology*. 2023, 14, 1083382. DOI: 10.3389/fendo.2023.1083382
- [127] Kour S, Fortuna T, Anderson EN, Mawrie D, Bilstein J, et al. Drosha-dependent microRNAs modulate FUS-mediated neurodegeneration in vivo. *Nucleic Acids Research*. 2023, 51(20), 11258-11276. DOI: 10.1093/nar/gkad774
- [128] Bağcı Ö, Özdemir EM, Şanlıtürk B. Variant Analysis of miRNA Regulatory Genes in 35 Sporadic Lung Carcinoma Tumors. *Doklady. Biochemistry and Biophysics*. 2023, 513(Suppl 1), S1-S7. DOI: 10.1134/S1607672924600052
- [129] Wang YM, Chen SY, Ta M, Senz J, Tao LV, et al. Biallelic Dicer1 Mutations in the Gynecologic Tract of Mice Drive Lineage-Specific Development of DICER1 Syndrome-Associated Cancer. *Cancer Research*. 2023, 83(21), 3517-3528. DOI: 10.1158/0008-5472.CAN-22-3620
- [130] Fang T, Wu QQ, Zhou L, Mu S, Fu Q. miR-106b-5p and miR-17-5p suppress osteogenic differentiation by targeting Smad5 and inhibit bone formation. *Experimental Cell Research*. 2016, 347(1), 74-82. DOI: 10.1016/j.yexcr.2016.07.010
- [131] Liu MY, Sun F, Feng YX, Sun XY, Li J, et al. MicroRNA-132-3p represses Smad5 in MC3T3-E1 osteoblastic cells under cyclic tensile stress. *Molecular and Cellular Biochemistry*. 2019, 458(1-2), 143-157. DOI: 10.1007/s11010-019-03538-3
- [132] Shu T, He L, Wang X, Pang M, Yang B, et al. Long noncoding RNA UCA1 promotes chondrogenic differentiation of human bone marrow mesenchymal stem cells via miRNA-145-5p/SMAD5 and miRNA-124-3p/SMAD4 axis. *Biochemical and Biophysical Research Communications*. 2019, 514(1), 316-322. DOI: 10.1016/j.bbrc.2019.04.140
- [133] Chen YZ, Zhou Y, Yang H, Li XW, Ding YL, et al. SMAD1 affects the proliferation, apoptosis and migration of colorectal cancer cells by regulating miR-32 expression. *Tumor*. 2022, (02), 77-92. DOI: 10.3781/j.issn.1000-7431.2022.2012-1148
- [134] Liu CY, Zhang YJ, Guo J, Sun W, Ji Y, et al. Overexpression of microRNA-93-5p and microRNA-374a-5p Suppresses the Osteogenic Differentiation and Mineralization of Human Aortic Valvular Interstitial Cells Through the BMP2/Smad1/5/RUNX2 Signaling Pathway. *Journal of Cardiovascular Pharmacology*. 2023, 82(2), 138-147. DOI: 10.1097/FJC.0000000000001440
- [135] Supadmanaba IGP, Mantini G, Randazzo O, Capula M, Muller IB, et al. Interrelationship between miRNA and splicing factors in pancreatic ductal adenocarcinoma. *Epigenetics*. 2022, 17(4), 381-404. DOI: 10.1080/15592294.2021.1916697
- [136] Erdem M, Özgül I, Erson-Bensan AE. HNRNPA1 (Heterogeneous nuclear ribonucleoprotein A1). *Atlas of Genetics and Cytogenetics in Oncology and Haematology*. 2019, 23(6), 137-142. DOI: 10.4267/2042/70455
- [137] Wen J, Ladewig E, Shenker S, Mohammed J, Lai EC. Analysis of Nearly One Thousand Mammalian Mirtrons Reveals Novel Features of Dicer Substrates. *PLoS Computational Biology*. 2015, 11(9), e1004441. DOI: 10.1371/journal.pcbi.1004441
- [138] Orlans HO, McClements ME, Barnard AR, Martinez-Fernandez de la Camara C, MacLaren RE. Mirtron-mediated RNA knockdown/replacement therapy for the treatment of dominant retinitis pigmentosa. *Nature Communications*. 2021, 12(1), 4934. DOI: 10.1038/s41467-021-25204-3
- [139] Berezikov E, Chung WJ, Willis J, Cuppen E, Lai EC. Mammalian Mirtron Genes. *Molecular Cell*. 2007, 28(2), 328-36. DOI: 10.1016/j.molcel.2007.09.028
- [140] Aparicio-Puerta E, Hirsch P, Schmartz GP, Fehlmann T, Keller V, et al. isomiRdb: microRNA expression at isoform resolution. *Nucleic Acids Research*. 2023, 51(D1), D179-D185. DOI: 10.1093/nar/gkac884
- [141] Gómez-Martín C, Aparicio-Puerta E, van Eijndhoven MAJ, Medina JM, Hackenberg M, et al. Reassessment of miRNA variant (isomiRs) composition by small RNA sequencing. *Cell Reports Methods*. 2023, 3(5), 100480. DOI: 10.1016/j.crmeth.2023.100480
- [142] Neilsen CT, Goodall GJ, Bracken CP. IsomiRs - The overlooked repertoire in the dynamic microRNAome. *Trends in Genetics: TIG*. 2012, 28(11), 544-9. DOI: 10.1016/j.tig.2012.07.005
- [143] Talukder A, Zhang WC, Li XM, Hu HY. A deep learning method for miRNA/isomiR target detection. *Scientific Reports*. 2022, 12(1), 10618. DOI: 10.1038/s41598-022-14890-8
- [144] Smith CM, Hutvagner G. A comparative analysis of single cell small RNA sequencing data reveals heterogeneous isomiR expression and regulation. *Scientific Reports*. 2022, 12(1), 2834. DOI: 10.1038/s41598-022-06876-3
- [145] Lukosevicius R, Alzbutas G, Varkalaite G, Salteniene V, Tilinde D, et al. 5'-Isoforms of miR-1246 Have Distinct Targets and Stronger Functional Impact Compared with Canonical miR-1246 in Colorectal Cancer Cells In Vitro. *International Journal of Molecular Sciences*. 2024, 25(5), 2808. DOI: 10.3390/ijms25052808
- [146] Ferre A, Santiago L, Sánchez-Herrero JF, López-Rodrigo O, Sánchez-Curbelo J, et al. 3'IsomiR Species Composition Affects Reliable Quantification of miRNA/isomiR Variants by Poly(A) RT-qPCR: Impact on Small RNA-Seq Profiling Validation. *International Journal of Molecular Sciences*. 2023, 24(20), 15436. DOI: 10.3390/ijms242015436
- [147] Guo L, Ren DK, Zhang YT, Wang QS, Yu SY, et al. A comprehensive pan-cancer analysis reveals cancer-associated robust isomiR expression landscapes in miRNA arm switching. *Molecular Genetics and Genomics: MGG*. 2023, 298(3), 521-535. DOI: 10.1007/s00438-023-01997-4
- [148] Zhiyanov A, Engibaryan N, Nersisyan S, Shkurnikov M, Tonevitsky A. Differential co-expression network

- analysis with DCoNA reveals isomiR targeting aberrations in prostate cancer. *Bioinformatics*. 2023, 39(2), btad051. DOI: 10.1093/bioinformatics/btad051
- [149] Aiso T, Ueda M. 5'-isomiR is the most abundant sequence of miR-1246, a candidate biomarker of lung cancer, in serum. *Molecular Medicine Reports*. 2023, 27(4), 92. DOI: 10.3892/mmr.2023.12979
- [150] Liang TM, Han L, Guo L. Rewired functional regulatory networks among miRNA isoforms (isomiRs) from let-7 and miR-10 gene families in cancer. *Computational and Structural Biotechnology Journal*. 2020, 18, 1238-1248. DOI: 10.1016/j.csbj.2020.05.001
- [151] Soto X, Biga V, Kursawe J, Lea R, Doostdar P, et al. Dynamic properties of noise and Her6 levels are optimized by miR-9, allowing the decoding of the Her6 oscillator. *The EMBO Journal*. 2020, 39(12), e103558. DOI: 10.15252/embj.2019103558
- [152] Goodfellow M, Phillips NE, Manning C, Galla T, Papalopulu N. MicroRNA input into a neural ultradian oscillator controls emergence and timing of alternative cell states. *Nature Communications*. 2014, 5, 3399. DOI: 10.1038/ncomms4399
- [153] Phillips NE, Manning CS, Pettini T, Biga V, Marinopoulou E, et al. Stochasticity in the miR-9/Hes1 oscillatory network can account for clonal heterogeneity in the timing of differentiation. *Elife*. 2016, 5, e16118. DOI: 10.7554/eLife.16118
- [154] Arvin P, Ghafouri S, Bavarsad K, Hajipour S, Khoshnam SE, et al. Exogenous growth hormone administration during total sleep deprivation changed the microRNA-9 and dopamine D2 receptor expressions followed by improvement in the hippocampal synaptic potential, spatial cognition, and inflammation in rats. *Psychopharmacology*. 2023, 240(6), 1299-1312. DOI: 10.1007/s00213-023-06369-9
- [155] Bamunuarachchi G, Vaddadi K, Yang XY, Dang QJ, Zhu ZY, et al. MicroRNA-9-1 Attenuates Influenza A Virus Replication via Targeting Tankyrase 1. *Journal of Innate Immunity*. 2023, 15(1), 647-664. DOI: 10.1159/000532063
- [156] Li B, Ding T, Chen HY, Li CW, Chen B, et al. CircStrn3 targeting microRNA-9-5p is involved in the regulation of cartilage degeneration and subchondral bone remodelling in osteoarthritis. *Bone & Joint Research*. 2023, 12(1), 33-45. DOI: 10.1302/2046-3758.121.BJR-2022-0231.R1
- [157] Xu JH, Zuo JR, Han CY, Li TT, Jin DX, et al. Proprotein convertase subtilisin/kexin 9 inhibitor downregulates microRNA-130a-3p expression in hepatocytes to alleviate atherosclerosis progression. *Naunyn-Schmiedeberg's Archives of Pharmacology*. 2024, 397(3), 1727-1736. DOI: 10.1007/s00210-023-02708-x
- [158] Walker JC, Harland RM. Expression of microRNAs during embryonic development of *Xenopus tropicalis*. *Gene Expression Patterns: GEP*. 2008, 8(6), 452-456. DOI: 10.1016/j.ggp.2008.03.002
- [159] Jatllon O, Aury JM, Brunet F, Petit JL, Stange-Thomann N, et al. Genome duplication in the teleost fish *Tetraodon nigroviridis* reveals the early vertebrate proto-karyotype. *Nature*. 2004, 431(7011), 946-57. DOI: 10.1038/nature03025
- [160] Chen PY, Manninga H, Slanchev K, Chien M, Russo JJ, et al. The developmental miRNA profiles of zebrafish as determined by small RNA cloning. *Genes & Development*. 2005, 19(11), 1288-93. DOI: 10.1101/gad.1310605
- [161] Mead EA, Wang YP, Patel S, Thekkumthala AP, Kepich R, et al. miR-9 utilizes precursor pathways in adaptation to alcohol in mouse striatal neurons. *Advances in Drug and Alcohol Research*. 2023, 3, 11323. DOI: 10.3389/adar.2023.11323
- [162] Kuang T, Li LS, Chen YL, Wang JJ. Effects of miR-9-5p on the migration, invasion and epithelial-mesenchymal transition process in cervical squamous cell carcinoma. *Journal of Central South University. Medical Sciences*. 2023, 48(1), 15-23. DOI: 10.11817/j.issn.1672-7347.2023.210773
- [163] Carvajal-Moreno J, Hernandez VA, Wang XY, Li JA, Yalowich JC, et al. Effects of hsa-miR-9-3p and hsa-miR-9-5p on Topoisomerase II β Expression in Human Leukemia K562 Cells with Acquired Resistance to Etoposide. *The Journal of Pharmacology and Experimental Therapeutics*. 2023, 384(2), 265-276. DOI: 10.1124/jpet.122.001429
- [164] Wang PW, Mao SL, Yi TT, Wang LH. LncRNA MALAT1 Targets miR-9-3p to Upregulate SAP97 in the Hippocampus of Mice with Vascular Dementia. *Biochemical Genetics*. 2023, 61(3), 916-930. DOI: 10.1007/s10528-022-10289-2
- [165] Expression of Concern: MicroRNA-9 inhibits high glucose-induced proliferation, differentiation and collagen accumulation of cardiac fibroblasts by down-regulation of TGFBR2. *Bioscience Reports*. 2023, 43(1), BSR-2016-0346 EOC. DOI: 10.1042/bsr-2016-0346_eoc
- [166] Ukey S, Jain A, Dwivedi S, Choudhury C, Vishnoi JR, et al. Study of MicroRNA (miR-221-3p, miR-133a-3p, and miR-9-5p) Expressions in Oral Submucous Fibrosis and Squamous Cell Carcinoma. *Indian Journal of Clinical Biochemistry: IJCB*. 2023, 38(1), 73-82. DOI: 10.1007/s12291-022-01035-x
- [167] Soto X, Burton J, Manning CS, Minchington T, Lea R, et al. Sequential and additive expression of miR-9 precursors control timing of neurogenesis. *Development*. 2022, 149(19), dev200474. DOI: 10.1242/dev.200474
- [168] Hajioghrari B, Farrokhi N. Investigation on the Conserved MicroRNA Genes in Higher Plants. *Plant Molecular Biology Reporter*. 2021, 39(12), 10-23. DOI: 10.1007/s11105-020-01228-9
- [169] Davila JL, Goff LA, Ricupero CL, Camarillo C, Oni EN, et al. A positive feedback mechanism that regulates expression of miR-9 during neurogenesis. *PLoS One*. 2014, 9(4), e94348. DOI: 10.1371/journal.pone.0094348
- [170] Bofill-De Ros X, Kasprzak WK, Bhandari Y, Fan L, Cavanaugh Q, et al. Structural Differences between PrimiRNA Paralogs Promote Alternative Drosha Cleavage and Expand Target Repertoires. *Cell Reports*. 2019, 26(2), 447-459.e4. DOI: 10.1016/j.celrep.2018.12.054
- [171] Telonis AG, Magee R, Loher P, Chervoneva I, Londin E, et al. Knowledge about the presence or absence of miRNA isoforms (isomiRs) can successfully discriminate amongst 32 TCGA cancer types. *Nucleic Acids Research*. 2017, 45(6), 2973-2985. DOI: 10.1093/nar/gkx082
- [172] Wu SJ, Xue QP, Qin XY, Wu XM, Kim P, et al. The Potential Regulation of A-to-I RNA Editing on Genes in Parkinson's Disease. *Genes*. 2023, 14(4), 919. DOI: 10.3390/genes14040919
- [173] Kumar RS, Sinha H, Datta T, Sharma A, Trivedi PK. Genome-Editing Tools for Engineering of MicroRNAs and Their Encoded Peptides, miPEPs, in Plants. *Applications of Genome Engineering in Plants*. 2024, 153-176. DOI: 10.1002/9781394183913.ch8
- [174] Lu QC, Zhou WH, Fan LG, Ding T, Wang W, et al. Tumor neoantigens derived from RNA editing events show significant clinical relevance in melanoma patients treated with immunotherapy. *Anti-cancer Drugs*. 2024, 35(3), 305-314. DOI: 10.1097/CAD.0000000000001565
- [175] Wan XY, Guo HP, Huang RH, Wang XQ, Zeng LY, et al. The Regulatory Function of ADAR1-mediated RNA Editing in Hematological Malignancies. *Progress in Biochemistry Biophysics*. 2024, 51(2), 300-308. DOI: 10.16476/j.pibb.2023.0037

- [176] de Sousa MC, Gjorgjieva M, Dolicka D, Sobolewski C, Foti M. Deciphering miRNAs' action through miRNA editing. *International Journal of Molecular Sciences*. 2019, 20(24), 6249. DOI: 10.3390/ijms20246249
- [177] Kabekkodu SP, Shukla V, Varghese VK, Adiga D, Vethil Jishnu P, et al. Cluster miRNAs and cancer: Diagnostic, prognostic and therapeutic opportunities. *Wiley Interdisciplinary Reviews. RNA*. 2020, 11(2), e1563. DOI: 10.1002/wrna.1563
- [178] Wang YM, Xu XY, Yu SX, Jeong KJ, Zhou Z, et al. Systematic characterization of A-to-I RNA editing hotspots in microRNAs across human cancers. *Genome Research*. 2017, 27(7), 1112-1125. DOI: 10.1101/gr.219741.116
- [179] Coolen M, Katz S, Bally-Cuif L. miR-9: A versatile regulator of neurogenesis. *Frontiers in Cellular Neuroscience*. 2013, 7, 220. DOI: 10.3389/fncel.2013.00220
- [180] Nowek K, Wiemer EAC, Jongen-Lavrencic M. The versatile nature of miR-9/9* in human cancer. *Oncotarget*. 2018, 9(29), 20838-20854. DOI: 10.18632/oncotarget.24889
- [181] Yuva-Aydemir Y, Simkin A, Gascon E, Gao FB. MicroRNA-9: Functional evolution of a conserved small regulatory RNA. *RNA Biology*. 2011, 8(4), 557-64. DOI: 10.4161/rna.8.4.16019
- [182] Beclin C, Bosio A, Cremer H. MicroRNAs in Neural Stem Cells. *MicroRNA in Regenerative Medicine*, Second Edition. 2015, 167-186. DOI: 10.1016/B978-0-12-820719-2.00006-5
- [183] Madelaine R, Sloan SA, Huber N, Notwell JH, Leung LC, et al. MicroRNA-9 Couples Brain Neurogenesis and Angiogenesis. *Cell Reports*. 2017, 20(7), 1533-1542. DOI: 10.1016/j.celrep.2017.07.051
- [184] Zhen JW, Zhang HX, Dong HZ, Tong XP. miR-9-3p inhibits glioma cell proliferation and apoptosis by directly targeting FOXG1. *Oncology Letters*. 2020, 20(2), 2007-2015. DOI: 10.3892/ol.2020.11725
- [185] Bonev B, Pisco A, Papalopulu N. MicroRNA-9 Reveals Regional Diversity of Neural Progenitors along the Anterior-Posterior Axis. *Developmental Cell*. 2011, 20(1), 19-32. DOI: 10.1016/j.devcel.2010.11.018
- [186] Moradi Z, Kazemi M, Jamshidi-Khalifelou R, Bahramnia V, Esfandmaz F, et al. CRISPR du-HITI an attractive approach to targeting Long Noncoding RNA HCP5 as inhibitory factor for proliferation of ovarian cancer cell. *Functional & Integrative Genomics*. 2024, 24(2), 61. DOI: 10.1007/s10142-024-01324-z
- [187] Giusti SA, Vogl AM, Brockmann MM, Vercelli CA, Rein ML, et al. MicroRNA-9 controls dendritic development by targeting REST. *Elife*. 2014, 3, e02755. DOI: 10.7554/eLife.02755
- [188] Radhakrishnan B, Alwin Prem Anand A. Role of miRNA-9 in brain development. *Journal of Experimental Neuroscience*. 2016, 10, 101-120. DOI: 10.4137/JEn.s32843
- [189] Wang SL, Jiang GH, Wang SX. Neuroprotective Role of MiRNA-9 in Neurological Diseases: A Mini Review. *Current Molecular Medicine*. 2023, 23(10), 1007-1011. DOI: 10.2174/1566524023666221025123132
- [190] Chen P, Price C, Li ZJ, Li YY, Cao DL, et al. miR-9 is an essential oncogenic microRNA specifically overexpressed in mixed lineage leukemia-rearranged leukemia. *Proceedings of the National Academy of Sciences of the United States of America*. 2013, 110(28), 11511-6. DOI: 10.1073/pnas.1310144110
- [191] Denli AM, Cao X, Gage FH. MiR-9 and TLX: Chasing tails in neural stem cells. *Nature Structural & Molecular Biology*. 2009, 16(4), 346-7. DOI: 10.1038/nsmb0409-346
- [192] Zhao CN, Sun GQ, Li SX, Shi YH. A feedback regulatory loop involving microRNA-9 and nuclear receptor TLX in neural stem cell fate determination. *Nature Structural & Molecular Biology*. 2009, 16(4), 365-71. DOI: 10.1038/nsmb.1576
- [193] Wu WY, Jing YC, Xu Q, Hao J, Yu X. MiR-9 promotes proliferation and inhibits apoptosis of bladder cancer cells via notch signaling pathway. *Panminerva Medica*. 2023, 65(1), 114-115. DOI: 10.23736/S0031-0808.19.03818-7
- [194] Roesse-Koerner B, Stappert L, Berger T, Braun NC, Veltel M, et al. Reciprocal Regulation between Bifunctional miR-9/9* and its Transcriptional Modulator Notch in Human Neural Stem Cell Self-Renewal and Differentiation. *Stem Cell Reports*. 2016, 7(2), 207-19. DOI: 10.1016/j.stemcr.2016.06.008
- [195] Chen X, Yang F, Zhang TZ, Wang W, Xi WJ, et al. MiR-9 promotes tumorigenesis and angiogenesis and is activated by MYC and OCT4 in human glioma. *Journal of Experimental & Clinical Cancer Research: CR*. 2019, 38(1), 99. DOI: 10.1186/s13046-019-1078-2
- [196] Fan YY, Shi Y, Lin ZH, Huang XX, Li JY, et al. miR-9-5p Suppresses Malignant Biological Behaviors of Human Gastric Cancer Cells by Negative Regulation of TNFAIP8L3. *Digestive Diseases and Sciences*. 2019, 64(10), 2823-2829. DOI: 10.1007/s10620-019-05626-2
- [197] Khosravi A, Alizadeh S, Jalili A, Shirzad R, Saki N. The impact of Mir-9 regulation in normal and malignant hematopoiesis. *Oncology Reviews*. 2018, 12(1), 348. DOI: 10.4081/oncol.2018.348
- [198] Chen L, Hu WF, Li GH, Guo YL, Wan ZH, et al. Inhibition of miR-9-5p suppresses prostate cancer progress by targeting StarD13. *Cellular & Molecular Biology Letters*. 2019, 24, 20. DOI: 10.1186/s11658-019-0145-1
- [199] Liu YJ, Wang C, Zhang CR, Chen RP, Liu BH, et al. Nonenzymatic Multiampified Electrochemical Detection of Medulloblastoma-Relevant MicroRNAs from Cerebrospinal Fluid. *ACS Sensors*. 2022, 7(8), 2320-2327. DOI: 10.1021/acssensors.2c00956
- [200] Ferretti E, De Smaele E, Po A, Marcotullio L Di, Tosi E, et al. MicroRNA profiling in human medulloblastoma. *International Journal of Cancer*. 2009, 124(3), 568-77. DOI: 10.1002/ijc.23948
- [201] Mollashahi B, Aghamaleki FS, Movafagh A. The Roles of miRNAs in Medulloblastoma: A Systematic Review. *Journal of Cancer Prevention*. 2019, 24(2), 79-90. DOI: 10.15430/jcp.2019.24.2.79
- [202] Yao XH, Xie LS, Zeng Y. MiR-9 Promotes Angiogenesis via Targeting on Sphingosine-1- Phosphate Receptor 1. *Frontiers in Cell and Developmental Biology*. 2020, 8, 755. DOI: 10.3389/fcell.2020.00755
- [203] Tantawy M, Elzayat MG, Yehia D, Taha H. Identification of microRNA signature in different pediatric brain tumors. *Genetics and Molecular Biology*. 2018, 41(1), 27-34. DOI: 10.1590/1678-4685-gmb-2016-0334
- [204] Tan XC, Wang S, Yang B, Zhu LY, Yin B, et al. The CREB-miR-9 Negative Feedback Minicircuitry Coordinates the Migration and Proliferation of Glioma Cells. *PLoS One*. 2012, 7(1), e49570. DOI: 10.1371/journal.pone.0049570
- [205] Zottel A, Šamec N, Kump A, Dall'olio LR, Dominkuš PP, et al. Analysis of miR-9-5p, miR-124-3p, miR-21-5p, miR-138-5p, and miR-1-3p in glioblastoma cell lines and extracellular vesicles. *International Journal of Molecular Sciences*. 2020, 21(22), 8491. DOI: 10.3390/ijms21228491
- [206] Chen XR, Zhang YG, Wang Q. miR-9-5p Mediates ABCB1 to Elevate the Sensitivity of Glioma Cells to Temozolomide. *Frontiers in Oncology*. 2021, 11, 661653. DOI: 10.3389/fonc.2021.661653

- [207] Liu JH, Zhu SL, Tang W, Huang QH, Mei Y, et al. Exosomes from tamoxifen-resistant breast cancer cells transmit drug resistance partly by delivering miR-9-5p. *Cancer Cell International*. 2021, 21(1), 55. DOI: 10.1186/s12935-020-01659-0
- [208] Sporn JC, Katsuta E, Yan L, Takabe K. Expression of microRNA-9 is associated with overall survival in breast cancer patients. *The Journal of Surgical Research*. 2019, 233, 426-435. DOI: 10.1016/j.jss.2018.08.020
- [209] Zhang JB, Cheng J, Zeng ZZ, Wang YF, Li XJ, et al. Comprehensive profiling of novel microRNA-9 targets and a tumor suppressor role of microRNA-9 via targeting IGF2BP1 in hepatocellular carcinoma. *Oncotarget*. 2015, 6(39), 42040-52. DOI: 10.18632/oncotarget.5969
- [210] Wang YK, Dong LF, Wan F, Chen FF, Liu DL, et al. MiR-9-3p regulates the biological functions and drug resistance of gemcitabine-treated breast cancer cells and affects tumor growth through targeting MTDH. *Cell Death & Disease*. 2021, 12(10), 861. DOI: 10.1038/s41419-021-04145-1
- [211] D'Ippolito E, Plantamura I, Bongiovanni L, Casalini P, Baroni S, et al. miR-9 and miR-200 regulate PDGFR β -mediated endothelial differentiation of tumor cells in triple-negative breast cancer. *Cancer Research*. 2016, 76(18), 5562-72. DOI: 10.1158/0008-5472.CAN-16-0140
- [212] Bao C, Lu YK, Chen JS, Chen DN, Lou WY, et al. Exploring specific prognostic biomarkers in triple-negative breast cancer. *Cell Death & Disease*. 2019, 10(11), 807. DOI: 10.1038/s41419-019-2043-x
- [213] Park S, Eom K, Kim J, Bang H, Wang H young, et al. MiR-9, miR-21, and miR-155 as potential biomarkers for HPV positive and negative cervical cancer. *BMC Cancer*. 2017, 17(11), 658. DOI: 10.1186/s12885-017-3642-5
- [214] Zhao X, Dong WL, Luo GF, Xie J, Liu J, et al. Cervical cancer treatment of Co(II) coordination polymer through miR-9-5p-regulated BRCA1-OCT1-GADD45 pathways. *Arabian Journal of Chemistry*. 2022, 5, 103713. DOI: 10.1016/j.arabjc.2022.103713
- [215] Peitz J, Stockett A, Chawla K, Carvajal DN, Plotkin A, et al. Identifying small non-coding RNAs as biomarkers for cervical cancer. *Journal of Clinical Oncology*. 2023, 41, 16. DOI: 10.1200/jco.2023.41.16_suppl.e17507
- [216] Liu CY, Wang XL, Zhang YZ. The Roles of HK2 on Tumorigenesis of Cervical Cancer. *Technology in Cancer Research & Treatment*. 2019, 18, 1533033819871306. DOI: 10.1177/1533033819871306
- [217] Wei YZ, Jiao XL, Zhang SY, Xu Y, Li S, et al. MiR-9-5p could promote angiogenesis and radiosensitivity in cervical cancer by targeting SOCS5. *European Review for Medical and Pharmacological Sciences*. 2019, 23(17), 7314-7326. DOI: 10.26355/eurrev_201909_18837
- [218] Guo ZY, Huang SC, Zhou YH, Cheng WJ, Chu X, et al. MicroRNA-9-5p functions as a tumor suppressor in prostate cancer via targeting utr. *EXCLI Journal*. 2019, 18. DOI: 10.17179/excli2019-1512
- [219] Wang X, Cai J, Zhao L, Zhang DJ, Xu GJ, et al. NUMB suppression by miR-9-5P enhances CD44+ prostate cancer stem cell growth and metastasis. *Scientific Reports*. 2021, 11(1), 11210. DOI: 10.1038/s41598-021-90700-x
- [220] Seashols-Williams SJ, Budd W, Clark GC, Wu Q, Daniel R, et al. MiR-9 acts as an OncomiR in prostate cancer through multiple pathways that drive tumour progression and metastasis. *PLoS One*. 2016, 11(7), e0159601. DOI: 10.1371/journal.pone.0159601
- [221] Sang ZM, Jiang XW, Guo LF, Yin G. MicroRNA-9 suppresses human prostate cancer cell viability, invasion and migration via modulation of mitogen-activated protein kinase kinase 3 expression. *Molecular Medicine Reports*. 2019, 19(5), 4407-4418. DOI: 10.3892/mmr.2019.10065
- [222] Bahrami A, Jafari A, Ferns GA. The dual role of microRNA-9 in gastrointestinal cancers: oncomiR or tumor suppressor? *Biomedicine and Pharmacotherapy*. 2022, 145, 112394. DOI: 10.1016/j.biopha.2021.112394
- [223] Gao HY, Huo FC, Wang HY, Pei DS. MicroRNA-9 inhibits the gastric cancer cell proliferation by targeting TNFAIP8. *Cell Proliferation*. 2017, 50(2), e12331. DOI: 10.1111/cpr.12331
- [224] Hang C, Yan HS, Gong C, Gao H, Mao QH, et al. MicroRNA-9 inhibits gastric cancer cell proliferation and migration by targeting neuropilin-1. *Experimental and Therapeutic Medicine*. 2019, 18(4), 2524-2530. DOI: 10.3892/etm.2019.7841
- [225] Liu T, Liu Y, Wei CQ, Yang Z, Chang WL, et al. LncRNA HULC promotes the progression of gastric cancer by regulating miR-9-5p/MYH9 axis. *Biomed Pharmacother*. 2020, 121, 109607. DOI: 10.1016/j.biopha.2019.109607
- [226] Cao SQ, Zheng H, Sun BC, Wang ZL, Liu T, et al. Long non-coding rna highly up-regulated in liver cancer promotes exosome secretion. *World Journal of Gastroenterology*. 2019, 25(35), 5283-5299. DOI: 10.3748/wjg.v25.i35.5283
- [227] Bao Y, Zhang YB, Lu YL, Guo HH, Dong ZH, et al. Overexpression of microRNA-9 enhances cisplatin sensitivity in hepatocellular carcinoma by regulating EIF5A2-mediated epithelial-mesenchymal transition. *International Journal of Biological Sciences*. 2020, 16(5), 827-837. DOI: 10.7150/ijbs.32460
- [228] Hadi N, Namazi F, Ketabchi F, Khosravian F, Nateghi B, et al. miR-574, miR-499, miR-125b, miR-106a, and miR-9 potentially target TGFBR-1 and TGFBR-2 genes involving in inflammatory response pathway: Potential novel biomarkers for chronic lymphocytic leukemia. *Pathology, Research and Practice*. 2022, 238, 154077. DOI: 10.1016/j.prp.2022.154077
- [229] Li S, Moffett HF, Lu J, Werner L, Zhang H, et al. MicroRNA expression profiling identifies activated B cell status in chronic lymphocytic leukemia cells. *PLoS One*. 2011, 6(3), e16956. DOI: 10.1371/journal.pone.0016956
- [230] Chen N, Feng LL, Qu HT, Lu K, Li PP, et al. Overexpression of IL-9 induced by STAT3 phosphorylation is mediated by miR-155 and miR-21 in chronic lymphocytic leukemia. *Oncology Reports*. 2018, 39(6), 3064-3072. DOI: 10.3892/or.2018.6367
- [231] Liu YH, Lei PC, Qiao H, Sun K, Lu XL, et al. MiR-9 enhances the chemosensitivity of AML cells to daunorubicin by targeting the EIF5A2/MCL-1 axis. *International Journal of Biological Sciences*. 2019, 15(3), 579-586. DOI: 10.7150/ijbs.29775
- [232] Zhu BK, Xi XP, Liu QQ, Cheng YY, Yang HP. MiR-9 functions as a tumor suppressor in acute myeloid leukemia by targeting CX chemokine receptor 4. *American Journal of Translational Research*. 2019, 11(6), 3384-3397. PMID: PMC6614627
- [233] Braoudaki M, Lambrou GI, Giannikou K, Milionis V, Stefanaki K, et al. MicroRNA expression signatures predict patient progression and disease outcome in pediatric embryonal central nervous system neoplasms. *Journal of Hematology & Oncology*. 2014, 7, 96. DOI: 10.1186/s13045-014-0096-y
- [234] Zhang Y, Dai G. Overexpression of microRNA-9 inhibits proliferation of human breast cancer cells by targeting stat3. *Tropical Journal of Pharmaceutical Research*. 2018, 17(9), 1753-1758. DOI: 10.4314/tjpr.v17i9.10
- [235] Lehmann U, Hasemeier B, Christgen M, Müller M, Römermann D, et al. Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer. *The*

- Journal of Pathology. 2008, 214(1), 17-24. DOI: 10.1002/path.2251
- [236] Baroni S, Romero-Cordoba S, Plantamura I, Dugo M, D'Ippolito E, et al. Exosome-mediated delivery of miR-9 induces cancer-Associated fibroblast-like properties in human breast fibroblasts. *Cell Death & Disease*. 2016, 7(7), e2312. DOI: 10.1038/cddis.2016.224
- [237] Selcuklu SD, Donoghue MTA, Rehmet K, De Gomes MS, Fort A, et al. MicroRNA-9 inhibition of cell proliferation and identification of novel miR-9 targets by transcriptome profiling in breast cancer cells. *The Journal of Biological Chemistry*. 2012, 287(35), 29516-28. DOI: 10.1074/jbc.M111.335943
- [238] Tian FX, Ma HF, Zhang Q. Identification of Mir-9 in glioma diagnosis and prognosis. *Clinical Laboratory*. 2020, 66(7). DOI: 10.7754/Clin.Lab.2019.190914
- [239] Zawistowski JS, Nakamura K, Parker JS, Granger DA, Golitz BT, et al. MicroRNA 9-3p Targets β 1 Integrin To Sensitize Claudin-Low Breast Cancer Cells to MEK Inhibition. *Molecular and Cellular Biology*. 2013, 33(11), 2260-74. DOI: 10.1128/mcb.00269-13
- [240] Ma NY, Li XH, Wei H, Zhang HJ, Zhang SL. Circular RNA circNFATC3 acts as a miR-9-5p sponge to promote cervical cancer development by upregulating SDC2. *Cellular Oncology*. 2021, 44(1), 93-107. DOI: 10.1007/s13402-020-00555-z
- [241] Babion I, Jaspers A, van Splunter AP, van der Hoorn IAE, Wilting SM, et al. MiR-9-5p exerts a dual role in cervical cancer and targets transcription factor TWIST1. *Cells*. 2019, 9(1), 65. DOI: 10.3390/cells9010065
- [242] Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. *CA: A Cancer Journal for Clinicians*. 2023, 73(1), 17-48. DOI: 10.3322/caac.21763
- [243] Wang L, Lu B, He MJ, Wang YQ, Wang ZP, et al. Prostate Cancer Incidence and Mortality: Global Status and Temporal Trends in 89 Countries From 2000 to 2019. *Frontiers in Public Health*. 2022, 10, 811044. DOI: 10.3389/fpubh.2022.811044
- [244] Walter BA, Valera VA, Pinto PA, Merino MJ. Comprehensive microRNA profiling of prostate cancer. *Journal of Cancer*. 2013, 4(5), 350-7. DOI: 10.7150/jca.6394
- [245] Zhang W, Shi CM, Xu Q, Chen XF, Zhu H, et al. Long non-coding RNA MIR22HG suppresses cell proliferation and promotes apoptosis in prostate cancer cells by sponging microRNA-9-3p. *Bioengineered*. 2022, 13(5), 13108-13117. DOI: 10.1080/21655979.2022.2079244
- [246] Wu M, Huang YW, Chen TC, Wang WC, Yang SG, et al. LncRNA MEG3 inhibits the progression of prostate cancer by modulating miR-9-5p/QKI-5 axis. *Journal of Cellular and Molecular Medicine*. 2019, 23(1), 29-38. DOI: 10.1111/jcmm.13658
- [247] Kanwal R, Plaga AR, Liu X, Shukla GC, Gupta S. MicroRNAs in prostate cancer: Functional role as biomarkers. *Cancer Letters*. 2017, 407, 9-20. DOI: 10.1016/j.canlet.2017.08.011
- [248] Sitarz R, Skierucha M, Mielko J, Offerhaus GJA, Maciejewski R, et al. Gastric cancer: Epidemiology, prevention, classification, and treatment. *Cancer Management and Research*. 2018, 10, 239-248. DOI: 10.2147/CMAR.S149619
- [249] Drakaki A, Hatzia Apostolou M, Polytarchou C, Vorvis C, Poultsides GA, et al. Functional microRNA high throughput screening reveals miR-9 as a central regulator of liver oncogenesis by affecting the PPARA-CDH1 pathway. *BMC Cancer*. 2015, 15, 542. DOI: 10.1186/s12885-015-1562-9
- [250] Si T, Huang LY, Liang T, Huang P, Zhang HY, et al. Ruangan Lidan decoction inhibits the growth and metastasis of liver cancer by downregulating miR-9-5p and upregulating PDK4. *Cancer Biology & Therapy*. 2023, 24(1), 2246198. DOI: 10.1080/15384047.2023.2246198
- [251] Rotkrupa P, Akiyama Y, Hashimoto Y, Otsubo T, Yuasa Y. MiR-9 downregulates CDX2 expression in gastric cancer cells. *International Journal of Cancer*. 2011, 129(11), 2611-20. DOI: 10.1002/ijc.25923
- [252] Lima JF, Carvalho J, Pinto-Ribeiro I, Almeida C, Wengel J, et al. Targeting miR-9 in gastric cancer cells using locked nucleic acid oligonucleotides. *BMC Molecular Biology*. 2018, 19(1), 6. DOI: 10.1186/s12867-018-0107-6
- [253] Wang LQ, Kwong YL, Kho CSB, Wong KF, Wong KY, et al. Epigenetic inactivation of miR-9 family microRNAs in chronic lymphocytic leukemia - Implications on constitutive activation of NF κ B pathway. *Molecular Cancer*. 2013, 12, 173. DOI: 10.1186/1476-4598-12-173
- [254] Price C, Chen P, Li ZJ, Li YY, Wiley A, et al. MLL-Rearranged Acute Myeloid Leukemias Drive Expression Of Mir-9, a Critical Oncogene In Leukemogenesis. *Blood*. 2013, 122(21), 3740. DOI: 10.1182/blood.v122.21.3740.3740
- [255] Tassone P, Di Martino MT, Arbitrio M, Fiorillo L, Staropoli N, et al. Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study. *Journal of Hematology & Oncology*. 2023, 16(1), 68. DOI: 10.1186/s13045-023-01468-8
- [256] Jiang XY, Abedi K, Shi JJ. Polymeric nanoparticles for RNA delivery. *Encyclopedia of Nanomaterials*. 2021. DOI: 10.1016/B978-0-12-822425-0.00017-8
- [257] Samad AFA, Kamaroddin MF. Innovative approaches in transforming microRNAs into therapeutic tools. *Wiley Interdisciplinary Reviews: RNA*. 2023, 14(1), e1768. DOI: 10.1002/wrna.1768
- [258] Bayraktar E, Bayraktar R, Oztatlici H, Lopez-Berestein G, Amero P, et al. Targeting miRNAs and Other Non-Coding RNAs as a Therapeutic Approach: An Update. *Non-coding RNA*. 2023, 9(2), 27. DOI: 10.3390/ncrna9020027
- [259] Rupaimoole R, Slack FJ. MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. *Nature Reviews Drug Discovery*. 2017, 16(3), 203-222. DOI: 10.1038/nrd.2016.246
- [260] Halloy F, Biscans A, Bujold KE, Debacker A, Hill AC, et al. Innovative developments and emerging technologies in RNA therapeutics. *RNA Biology*. 2022, 19(1), 313-332. DOI: 10.1080/15476286.2022.2027150
- [261] Cristina Caroleo M, De Sarro G. Overview of microRNA-based therapeutics. *MicroRNA: From Bench to Bedside*. 2022, 493-502. DOI: 10.1016/B978-0-323-89774-7.00027-3
- [262] Xia SQ, Xu CR, Liu FY, Chen G. Development of microRNA-based therapeutics for central nervous system diseases. *European Journal of Pharmacology*. 2023, 956, 17956. DOI: 10.1016/j.ejphar.2023.175956
- [263] Bolloix A, Feiner-Gracia N, Köber M, Repetto J, Pascarella R, et al. Engineering pH-Sensitive Stable Nanovesicles for Delivery of MicroRNA Therapeutics. *Small*. 2022, 18(3), e2101959. DOI: 10.1002/sml.202101959
- [264] Seyhan AA. Trials and Tribulations of MicroRNA Therapeutics. *International Journal of Molecular Sciences*. 2024, 25(3), 1469. DOI: 10.3390/ijms25031469
- [265] Di Martino MT, Riillo C, Scionti F, Grillone K, Polerà N, et al. Mirnas and lncrnas as novel therapeutic targets to improve cancer immunotherapy. *Cancers*. 2021, 13(7), 1587. DOI: 10.3390/cancers13071587

- [266] Ling H. Non-coding RNAs: Therapeutic strategies and delivery systems. *Advances in Experimental Medicine and Biology*. 2016, 937, 229-37. DOI: 10.1007/978-3-319-42059-2_12
- [267] Ferdows BE, Patel DN, Chen W, Huang XG, Kong N, et al. RNA cancer nanomedicine: nanotechnology-mediated RNA therapy. *Nanoscale*. 2022, 14(12), 4448-4455. DOI: 10.1039/d1nr06991h
- [268] Lin YX, Wang Y, Blake S, Yu M, Mei L, et al. RNA nanotechnology-mediated cancer immunotherapy. *Theranostics*. 2020, 10(1), 281-299. DOI: 10.7150/thno.35568
- [269] Lee SWL, Paoletti C, Campisi M, Osaki T, Adriani G, et al. MicroRNA delivery through nanoparticles. *Journal of Controlled Release*. 2019, 313, 80-95. DOI: 10.1016/j.jconrel.2019.10.007
- [270] Fresacher-Scheiber K, Ruseska I, Siboni H, Reiser M, Falsone F, et al. Modified Stability of microRNA-Loaded Nanoparticles. *Pharmaceutics*. 2022, 14(9), 1829. DOI: 10.3390/pharmaceutics14091829
- [271] Sufian MA, Iliès MA. Lipid-based nucleic acid therapeutics with in vivo efficacy. *Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology*. 2023, 15(2), e1856. DOI: 10.1002/wnan.1856
- [272] Cheng X, Lee RJ. The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery. *Advanced Drug Delivery Reviews*. 2016, 99, 129-137. DOI: 10.1016/j.addr.2016.01.022
- [273] Mohammadian F, Pilehvar-Soltanahmadi Y, Zarghami F, Akbarzadeh A, Zarghami N. Upregulation of miR-9 and Let-7a by nanoencapsulated chrysin in gastric cancer cells. *Artificial Cells, Nanomedicine, and Biotechnology*. 2017, 45(6), 1-6. DOI: 10.1080/21691401.2016.1216854
- [274] Wu Y, Tang YX, Xie SZ, Zheng XX, Zhang SF, et al. Chimeric peptide supramolecular nanoparticles for plectin-1 targeted miRNA-9 delivery in pancreatic cancer. *Theranostics*. 2020, 10(3), 1151-1165. DOI: 10.7150/thno.38327
- [275] MacDonagh L, Gallagher MF, Ffrench B, Gasch C, Gray SG, et al. MicroRNA expression profiling and biomarker validation in treatment-naïve and drug resistant non-small cell lung cancer. *Translational Lung Cancer Research*. 2021, 10(4), 1773-1791. DOI: 10.21037/tlcr-20-959
- [276] Yan H, Tang SJ, Tang SJ, Zhang J, Guo HY, et al. miRNAs in anti-cancer drug resistance of non-small cell lung cancer: Recent advances and future potential. *Frontiers in Pharmacology*. 2022, 13, 949566. DOI: 10.3389/fphar.2022.949566
- [277] Wei YF, Lai XF, Yu ST, Chen S, Ma YZ, et al. Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells. *Breast Cancer Research and Treatment*. 2014, 147(2), 423-31. DOI: 10.1007/s10549-014-3037-0
- [278] Li Y, Zhao LF, Li NN, Miao Y, Zhou HM, et al. MiR-9 regulates the multidrug resistance of chronic myelogenous leukemia by targeting ABCB1. *Oncology Reports*. 2017, 37(4), 2193-2200. DOI: 10.3892/or.2017.5464
- [279] Zhao HM, Wei W, Sun YH, Gao JH, Wang Q, et al. MicroRNA-9 promotes tumorigenesis and mediates sensitivity to cisplatin in primary epithelial ovarian cancer cells. *Tumour Biology*. 2015, 36(9), 6867-73. DOI: 10.1007/s13277-015-3399-x
- [280] Li QL, Chang YN, Mu LY, Song YW. MicroRNA-9 enhances chemotherapy sensitivity of glioma to TMZ by suppressing TOPO II via the NF-κB signaling pathway. *Oncology Letters*. 2019, 17(6), 4819-4826. DOI: 10.3892/ol.2019.10158
- [281] Kania EE, Carvajal-Moreno J, Hernandez VA, English A, Papa JL, et al. Hsa-miR-9-3p and hsa-miR-9-5p as Post-Transcriptional Modulators of DNA Topoisomerase IIa in Human Leukemia K562 Cells with Acquired Resistance to Etoposide. *Molecular Pharmacology* 2020, 97(3), 159-170. DOI: 10.1124/MOL.119.118315